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ABSTRACT 
 
Asparagine (N)-linked glycosylation occurs on 90% of membrane and 
secretory proteins and drives folding and trafficking along the secretory pathway. 
The N-glycan can be attached to an N-X-T/S-Y (X,Y ≠ P) consensus site by one 
of two oligosaccharyltransferase (OST) STT3 enzymatic isoforms either during 
protein translation (co-translational) or after protein translation has completed 
(post-translational). While co-translational N-glycosylation is both rapid and 
efficient, post-translational N-glycosylation occurs on a much slower time scale 
and, due to competition with protein degradation and forward trafficking, could be 
detrimental to the success of a peptide heavily reliant on post-translational N-
glycosylation. In evidence, mutations in K+ channel subunits that shift N-
glycosylation kinetics have been directly linked to cardiac arrhythmias. My thesis 
work focuses on identifying primary sequence factors that affect the rate of N-
glycosylation. 
To identify the molecular determinants that dictate whether a consensus 
site acquires its initial N-glycan during or after protein synthesis, I used short (~ 
100-170 aa) type I transmembrane peptides from the KCNE family (E1-E5) of K+ 
channel regulatory subunits. The lifetime of these small membrane proteins in 
the ER translocon is short, which places a significant time constraint on the co-
translational N-glycosylation machinery and increases the resolution between co- 
and post-translational events.  Using rapid metabolic pulse-chase experiments 
vi
described in Chapter II, I identified several molecular determinants among native 
consensus sites in the KCNE family that favor co-translational N-glycosylation: 
threonine containing-consensus sites (NXT), multiple N-terminal consensus sites, 
and long C-termini. The kinetics could also be shifted towards post-translational 
N-glycosylation by converting to a serine containing-consensus site (NXS), 
reducing the number of consensus sites in the peptide, and shortening the C-
termini. 
 In Chapter III, I utilized an E2 scaffold peptide to examine the N-
glycosylation kinetics of the middle X residue in an NXS consensus site. I found 
that large hydrophobic and negatively charged residues hinder co-translational 
N-glycosylation, while polar, small hydrophobic, and positively charged residues 
had the highest N-glycosylation efficiencies. Poorly N-glycosylated NXS 
consensus sites with large hydrophobic and negatively charged X residues had a 
significantly improved co-translational N-glycosylation efficiency upon conversion 
to NXT sites. 
Also in Chapter III, I adapted a siRNA knockdown strategy to definitively 
identify the OST STT3 isoforms that perform co- and post-translational N-
glycosylation for type I transmembrane substrates. I found that the STT3A 
isoform predominantly performs co-translational N-glycosylation while the STT3B 
isoform predominantly performs post-translational N-glycosylation, in agreement 
with the roles of these enzymatic subunits on topologically different substrates. 
vii
 Taken together, these findings further the ability to predict the success of 
a consensus site by primary sequence alone and will be helpful for the 
identification and characterization of N-glycosylation deficiency diseases. 
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PREFACE 
 
The experimental work in Chapter II has been published in a peer-
reviewed journal. Reference to publication that represent the work contained 
within this chapter: 
 
H.L.H. Malaby, W.R. Kobertz, Molecular determinants of co- and post-
translational N-glycosylation of type I transmembrane peptides, Biochem J 453 
(2013) 427-434. 
 
The experimental work in Chapter III has been written up as a manuscript 
for publication at the time of this thesis publication. I created all peptide 
constructs and performed all assays. Dr. Natalia Cherepanova is credited with 
designing the STT3 siRNAs used in CHO cells for the work in Chapter III. I 
designed the scrambled STT3 siRNAs also presented in Chapter III.  
Dr. Karen Mruk developed the terpyridine linker strategy used in Appendix 
II. Dr. Mruk also provided the terpyridine precursors used in the linker synthesis.
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CHAPTER I: INTRODUCTION 
 
Asparagine (N)-linked glycosylation is an essential physiological process 
driving glycoprotein trafficking to the plasma membrane and along the secretory 
pathway. This process begins either during or after protein translation, when a 
14-sugar lipid-linked oligosaccharide (LLO) is attached at a protein consensus 
site of N-X-T/S-(Y), where X and Y can be any amino acid other than proline [1]. 
The timing and affinity of these attachment steps has been shown to be 
instrumental for efficient processing further along the trafficking and secretory 
pathways, and an inability to meet the temporal demands on forward trafficking 
can result in disease [2,3]. Discussed here is an overview of the proteins and 
systems involved in trafficking a newly synthesized peptide from translation to 
LLO attachment, protein folding, and endoplasmic reticulum (ER) exit along the 
secretory pathway. Ideal peptide candidates for studying N-glycosylation are the 
KCNE family, small K+ channel regulatory subunits that are heavily N-
glycosylated. Their physiological relevance and known N-glycosylation deficiency 
diseases will be discussed in length. 
 
Co-translational translocation and membrane insertion 
Co-translational translocation begins by relocating an actively translating 
ribosome to the cytosolic face of the ER membrane. During protein translation, 
the signal recognition particle (SRP) reads and binds to an ER signal sequence 
1
on a growing peptide (nascent) chain in the cytosol [4,5] (Figure I-1A). This signal 
sequence can be either a cleavable N-terminal sequence composed of ~10-30 
predominantly hydrophobic amino acids, or the hydrophobic sequence of the first 
transmembrane domain [5]. A cryo-EM structure of the mammalian SRP showed 
that the SRP54 subunit is responsible for binding and protecting the nascent 
chain by lining the exposed surface with hydrophobic residues [6] (Figure I-1B). 
Further, a kink in the RNA chain of the SRP allows for a sharp angle in the 
complex. This places the SRP9 and SRP14 proteins near binding sites for 
elongation factors on the 60S ribosome, which supports the observation that 
translation is slowed while the SRP is bound to the ribosome and peptide 
nascent chain [4,6].  
The SRP relocates the ribosome/peptide complex to the ER membrane 
and attaches to an SRP binding site on the SRP receptor, hydrolyzing GTP to 
GDP. This interaction shifts the SRP ribosome complex, which is thought to allow 
a portion of the ribosomal exit tunnel to bind a nearby Sec61 complex 
(translocon) and cause the SRP to disassociate from the ribosome and nascent 
chain (Figure I-1A) [7,8]. There is also evidence that TRAM (translocating chain-
associated membrane protein) binds the peptide signal sequence after the SRP 
to aid in efficient translocation [9].  
What happens to the peptide next depends on the topology of the peptide 
being translated. A water-soluble peptide will move through the translocon tunnel 
into the ER lumen by ribosomal translational driving force. Once translation is 
2
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Figure I-1. Co-translational translocation and peptide targeting by the SRP  
(A) Cartoon depiction of co-translational translocation. (I) SRP binds to and 
protects a hydrophobic signal sequence once it leaves the translation tunnel of 
the ribosome and contacts the ribosome to stall translation. (II) The SRP 
relocates the complex to the ER membrane where the SRP docks with the SRP 
receptor via GTP, which allows (III) the ribosome to dock with the translocon and 
the peptide to diffuse into the translocon tunnel. GTP hydrolysis releases SRP. 
(B) Molecular model of the SRP as determined by cryo-EM. SRP54 = purple (M-
domain dark purple, NG-domain light purple); SRP19 = orange; SRP9 = green; 
SRP14 = yellow; peptide nascent chain = blue; gray = RNA. Inset. Hydrophobic 
residues of SRP54 are colored yellow. 
 
Co-translational translocation scheme made by H. Malaby. SRP structure 
generated from PBD: 1RY1. Reference: M. Halic, T. Becker, M.R. Pool, C.M. 
Spahn, R.A. Grassucci, J. Frank, R. Beckmann, Structure of the signal 
recognition particle interacting with the elongation-arrested ribosome, Nature 427 
(2004) 808-814. 
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complete, the peptide will move completely out of the translocon through the 
lumen for folding and assembly [10]. Transmembrane proteins will initially 
proceed similarly; however, since the hydrophobic ER signal sequence 
recognized by the SRP is the transmembrane domain, the transmembrane of the 
nascent peptide is fed into the translocon tunnel upon ribosomal docking (Figure 
I-2). The nascent peptide then most likely samples orientations of the 
transmembrane sequence until a favored outcome with the lowest free energy is 
achieved [8]. To aid in the process, many transmembrane protein sequences 
contain a string of positively charged residues located on the destined cytosolic 
domain and adjacent to the transmembrane domain [11]. This may also serve as 
an ER retention signal depending on the residues proximity to the C-terminus 
[12]. For type I transmembrane peptides, where the N-terminus is located in the 
ER lumen, this results in the bolus of the N-terminus unfolding all at once into the 
ER lumen. For type II transmembrane peptides, where the C-terminus is located 
in the ER lumen, this results in the N-terminus diffusing back out into the cytosol, 
and the remaining nascent chain being fed through the tunnel into the ER lumen 
[8]. Once the hydrophobic residues making up the transmembrane region are 
favorably oriented in the translocon tunnel, this section of the nascent chain will 
diffuse laterally out of the translocon and into the ER membrane [8,13].  
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Figure I-2. Membrane orientation determination for type I and type II 
transmembrane peptides. Once the ribosome is docked with the Sec61 
translocon complex, the peptide is inserted TM domain first. The TM then 
samples orientation through diffusion in the translocon tunnel. Type I TM 
peptides (right) often contain a string of positively charged residues at the 
beginning of the C-terminus, disfavoring diffusion into a hydrophobic tunnel. The 
N-terminus then preferentially diffuses into the ER lumen. Type II TM peptides 
(left) proceed similarly, but these often contain the positively charged residues at 
the end of the N-terminus, disfavoring entry into the translocon, while the C-
terminus diffuses through the translocon tunnel. 
 
Schematic generated by H. Malaby. 
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The Oligosaccharyltransferase (OST) and Co-translational N-glycosylation 
Regardless of the final topology of a nascent chain through the translocon, 
once the peptide enters the ER lumen it is recognized by the 
oligosaccharyltransferase (OST), which scans the nascent chain for N-
glycosylation consensus sites and attaches a preassembled oligosaccharide onto 
the consensus site asparagine [14,15]. N-glycosylation that occurs adjacently to 
Sec61 complex translocation and ribosomal translation of a peptide is termed co-
translational N-glycosylation [16], and is conserved from arachea and eubacteria 
to fungi, insects, plants and vertebrates. All of these organisms contain at least 
an enzymatic homolog of the OST [17]. The mammalian OST is composed of 
seven subunits, each thought to perform a unique function for this highly 
specialized complex (Figure I-3). STT3 is the main catalytic subunit actually 
orchestrating the glycan attachment to the peptide and has two isoforms 
designated STT3A and STT3B that share 60% sequence identity but have 
distinct enzymatic properties [18,19]. Ribophorin I and Ribophorin II may contact 
the ribosome and the translocon [20] and OST48 may act as a linking bridge 
between Ribophorin I and II. DADI is thought to provide structural integrity to the 
complex as a whole [21]. N33/Tusc3 or IAP/MagT1 have oxidoreductase 
capability that might aid in oxidative folding of peptide substrates for efficient N-
glycan attachment [22], and OST4 is thought to regulate the incorporation of 
N33/Tusc3 and IAP/MagT1 [21,23]. 
7
 
Figure I-3. Subunits of the Oligosaccharyltransferase (OST). Subunits 
composing the mammalian OST are depicted. Multiple isoforms indicated where 
appropriate. 
 
Cartoon representations generated by H. Malaby. STT3 structure (homolog from 
bacterial PglB) generated from PBD: 3RCE. Reference: C. Lizak, S. Gerber, S. 
Numao, M. Aebi, K.P. Locher, X-ray structure of a bacterial 
oligosaccharyltransferase, Nature 474 (2011) 350-355. 
 
OST4 structure (homolog from S. cerevisiae) generated from PBD: 1RKL. 
Reference: S. Zubkov, W.J. Lennarz, S. Mohanty, Structural basis for the 
function of a minimembrane protein subunit of yeast oligosaccharyltransferase, 
Proc Natl Acad Sci USA 101 (2004) 3821-3826. 
 
N33/TUSC3/IAP luminal structure (homolog from S. cerevisiae subunit OST6, 
oxidized) generated from PBD: 3G7Y. 
Reference: B.L. Schulz, C.U. Stirnimann, J.P. Grimshaw, M.S. Brozzo, F. Fritsch, 
E. Mohorko, G. Capitani, R. Glockshuber, M.G. Grutter, M. Aebi, Oxidoreductase 
activity of oligosaccharyltransferase subunits Ost3p and Ost6p defines site-
specific glycosylation efficiency, Proc Natl Acad Sci U S A 106 (2009) 11061-
11066. 
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Although the OST subunits have been identified, many of the details for 
assembly and function of the OST have yet to be determined [24]. It is known 
that the OST complex exists in heterogeneous populations in yeast and 
mammalian cells (because of the STT3A/STT3B and Tusc3/MagT1 subunit 
isoforms there might be as many as four possible mammalian OST isoforms), 
and these isoform ratios are uniquely distributed in different tissues [18]. What 
subunits are present in which isoforms and how the complex is arranged has yet 
to be elucidated. 
Despite these uncertainties, the conservation of an enzymatic subunit 
from vertebrates to bacteria and the recently determined crystal structures of the 
OST STT3A/B homologs for bacterial C. lari PglB [25] (Figure I-4) and aracheal 
A. fulgidus AglB [26] allow for a proposed general mechanism of LLO attachment 
to a peptide. As the nascent chain leaves the translocon tunnel, it is 
thermodynamically bound by a region bridging the transmembrane and 
periplasmic domains of the catalytic protein, which causes an external loop (EL5) 
to become ordered and pin the peptide against the periplasmic domain to restrict 
motion [25]. When an N-linked consensus site of N-X-T/S-Y, where X and Y can 
be any amino acid besides proline, orients in the peptide binding site (Figure I-4, 
top inset), the hydroxyl residue (T/S) is coordinated through hydrogen bonding 
between a number of tryptophan and aspartic acid OST residues creating a 
binding pocket that is thought to help stabilize the nascent chain [27]. There is 
also NMR evidence that this binding pocket is highly flexible, which might 
9
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Figure I-4. The bacterial OST homolog structure PglB. Crystal structure of 
PglB, homolog to STT3, the enzymatic subunit of the OST shown in green. The 
ten amino acid long peptide crystalized in the peptide binding site is depicted in 
blue with highlights for the consensus site: N (red), A (yellow), T (purple). Top 
inset: View rotated 90° counterclockwise and zoomed. Note the curvature of the 
peptide around the consensus site. Left bottom inset: Sphere fill of top image. 
Right bottom inset: View rotated 180° clockwise. Note how Asn is the only 
amino acid of the peptide that is exposed to the LLO binding and catalytic site. 
 
PglB structures generated from PBD: 3RCE. Reference: C. Lizak, S. Gerber, S. 
Numao, M. Aebi, K.P. Locher, X-ray structure of a bacterial 
oligosaccharyltransferase, Nature 474 (2011) 350-355. 
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facilitate efficient scanning of the peptide [28]. When the peptide is properly 
aligned, only the functional group of the consensus site asparagine is accessible 
from the LLO binding and catalytic site (Figure I-4, bottom insets). The 
asparagine is coordinated between a divalent cation (usually Mg2+ or Mn2+), a 
glutamic acid, an arginine, and three aspartic acid OST residues. Though the 
precise mechanism is yet to be fully understood, this group is thought to undergo 
hydrogen swapping, resulting in an activated amide nitrogen in the consensus 
site asparagine, holding the asparagine functional group in a triplanar orientation. 
The nitrogen is then able to undergo a nucleophilic attack on the adjacently 
positioned C1 carbon of a LLO (presumably coordinated by the OST as well), 
creating a peptide bond and attaching the oligosaccharide to the asparagine [25]. 
Once an oligosaccharide is attached to the consensus site asparagine 
residue, the steric tension caused by the newly bonded glycan is thought to 
cause the OST to release the glycopeptide, specifically by displacing the EL5 
which rapidly becomes unstructured causing disassembly of the peptide and LLO 
binding sites [25]. At this point the OST can repeat the process for additional 
consensus sites until translation is complete and the peptide moves out of range 
of the translocon and OST. For the two mammalian OST enzymatic isoforms, 
STT3A has been shown to be primarily associated with co-translational N-
glycosylation, and is believed to interact directly with the translocon [29]. The 
STT3B isoform has been associated with post-translational N-glycosylation [30]. 
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Post-translational N-glycosylation 
A “clean up” mechanism for skipped N-linked consensus sites 
 The first evidence for post-translational N-glycosylation was identified with 
a number of peptide fragments in vivo [31] and larger proteins treated with N-
glycosylation inhibitors [32,33]. However, since these studies were not of full-
length proteins under homeostatic conditions, it was not understood if post-
translational N-glycosylation was a normal cellular process. Post-translational N-
glycosylation was also found to occur for a truncated peptide processing enzyme 
PAM; while the peptide truncation is a normal part of PAM processing, this 
happens downstream of N-glycosylation leaving the elusive question for a 
physiological role of post-translational N-glycosylation unanswered [34]. The first 
physiologically relevant post-translational N-glycosylation substrates identified 
were Wg, a Wnt secreted glycoprotein in Drosphila that needs a Porc chaperone 
to prevent folding and keep the N-glycosylation site available [35], and Factor VII, 
a human coagulation protein [36]. Factor VII was identified as a post-translational 
N-glycosylation substrate using a rapid pulse-chase assay to observe the kinetics 
of N-glycan attachment. This study found that the glycoforms of factor VII 
significantly increased after only 15 minutes of chase, indicating that N-glycans 
can be attached relatively quickly after protein translation has been completed 
[36]. Since then, a number of other proteins have also been found to contain 
post-translational N-glycosylation sites [2,37,38,39,40,41]. 
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 Recently, the OST enzymatic isoform STT3B was implicated in the 
mechanism of post-translational N-glycan attachment for water soluble, type II, 
and multi-spanning transmembrane proteins (Figure I-5) [30,41,42]. Using a 
series of selected OST isoform siRNA knockdowns, it was shown that only the 
STT3B isoform performs post-translational N-glycan attachment [30]. The STT3A 
isoform largely performs co-translational N-glycan attachment, but interestingly 
the STT3B isoform can also N-glycosylate in a co-translational manner if the 
STT3A isoform is knocked down, albeit at a reduced efficiency [30]. 
 Overall, post-translational N-glycosylation by the STT3B isoform appears 
to contribute to quality control [43]. While STT3A attaches N-glycans at high 
efficiency, there are some sites that, for poorly understood reasons, are skipped 
by the co-translational N-glycosylation machinery. Presumably, these are the 
sites that the OST isoform STT3B attempts to find and glycosylate. While there is 
no evidence that the STT3B isoform actually attaches N-glycans at a reduced 
rate, in fact it seems to process oligosaccharides much faster [18], it is most 
likely hindered by the distance needed for diffusion to find proteins with skipped 
N-glycosylation consensus sites. While the STT3A isoform has very high local 
concentration of potential peptide substrate from association with the translocon, 
the STT3B isoform must work against potentially vast luminal space, protein 
folding, forward trafficking, and protein degradation. As such, the OST STT3B 
isoform appears less efficient in in vivo kinetic assays [40]. 
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Figure I-5. Post-translational N-glycosylation. (A) Schematic for post-
translational N-glycosylation of water-soluble proteins. While normal co-
translational translocation occurs and the OST STT3A enzymatic isoform is 
present, some consensus sites are not N-glycosylated by this machinery. 
Instead, the protein exits the translocon into the ER lumen and these consensus 
sites are later N-glycosylated by the OST STT3B isoform. (B) A similar 
mechanism is proposed for TM proteins. Here, the protein exits the translocon by 
lateral diffusion into the ER membrane. 
 
Schematic generated by H. Malaby. 
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Post-translational translocation 
 Recently, a number of protein classes have been shown to not utilize a co-
translational translocation insertion mechanism [8]. Signal sequences that are 
only slightly hydrophobic might not be recognized by the SRP, as well as 
peptides where the secondary structure of the signal sequence is inadequate for 
binding. Secretory proteins that are shorter than the length of the ribosomal exit 
tunnel (40-50 amino acids) will be skipped by the SRP because translation will 
have finished by the time the SRP can direct the ER targeting of these peptides 
[44]. Type II transmembrane proteins with short C-termini (termed tail-anchored 
(TA) proteins) have also been shown to be post-translational translocation 
substrates for similar reasons [45].  
For all substrates of SRP-independent mechanisms of translocation, the 
first proteins to bind the peptides after leaving the ribosomal exit tunnel are 
chaperones (Figure I-6). Hsp70, Hsp40, calmodulin, Sgt2, and Bag6 have all 
been identified as “first responder” chaperones for a variety of peptide substrates 
[44]. The Bag6 chaperone has been found to actually bind to translating 
ribosomes, deftly positioned to bind a nascent peptide chain [46]. These 
chaperones then pass off the peptide substrate to a protein targeting complex. A 
specific chaperone for TA proteins has been identified as the transmembrane 
domain recognition complex (TRC), composed of proteins Get3 and/or TRC40 
[45]. The pass off between chaperone and TRC is accomplished through a 
mediator complex composed of TRC35 and Ubl4A [44]. Structural studies of 
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Figure I-6. Post-translational translocation. Post-translational translocation 
occurs when the pathway for co-translational translocation via the SRP is 
unavailable due to an inability to bind the ER signal sequence. When the peptide 
exits the ribosome, a chaperone protein binds the hydrophobic signal sequence 
(ex. Hsp70, Hsp40, calmodulin, Sgt2, Bag6). Protein targeting complexes (ex. 
Get3, TRC40) can bind to or replace the chaperones on the peptide substrate 
and relocate the complex to the ER membrane. The translocation of the peptide 
occurs through either the Sec61 translocon in complex with Sec62 and Sec63 for 
small peptides or peptides with mild hydrophobic signal sequences or through 
the WRB/Get1 and CAML/Get2 complex for TA proteins. It is not known if 
WRB/Get1 or CAML/Get2 forms a translocon pore. 
 
Schematic generated by H. Malaby. 
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Get3 have shown that it functions as a dimer that fluctuates between “open” and 
“closed” states. The open state exposes a hydrophobic grove that could bind the 
transmembrane domain of a TA protein [47,48].  
The protein targeting machinery then relocates the complex to one of two 
possible post-translational translocational channels in the ER membrane: Sec61 
with the Sec62-Sec63 complex or Get1/WRB complexed with Get2/CAML [44]. 
Sec61 is the most common translocon in the ER membrane and is usually 
responsible for co-translational translocation. However, Sec61 has been shown 
to form a unique complex (termed the Sec complex) with Sec62 and Sec63 
proteins that convert this translocon for post-translational translocation tasks 
(Sec66 and Sec72 also have nonessential roles in the complex in yeast) [49].  
Small, less hydrophobic substrates are often targeted to the Sec complex. Here, 
the substrates diffuse through the translocon until one end can be bound and 
ratcheted through (or presumably into) the membrane by Kar2, which associates 
with Sec63.  
The Get1/WRB complexed with Get2/CAML translocon is unique in that 
an actual pore for translocation has yet to be identified. The mechanism of 
translocation is still not well understood although it does appear to be specific for 
TA proteins. It is thought that the TMs of this complex could arrange to allow the 
TM of a TA protein to wedge into the membrane through local membrane 
distortion, or even create a temporary gap for proteins to diffuse through into the 
lumen [44]. 
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 It is unknown how N-glycosylation occurs for post-translationally 
translocated proteins, but it is known that they can be glycosylated in mammalian 
cells when a glycosylation consensus site is introduced [50]. By definition these 
proteins would be post-translationally N-glycosylated, but it is not known which 
enzymatic isoform of the OST would attach the N-glycan. It is possible that the 
co-translational N-glycosylation machinery (OST STT3A) cannot assemble with 
Sec61 when it is complexed as a post-translational translocon or with the 
Get1/WRB complexed with Get2/CAML translocon, which would indicate that 
STT3A mediated N-glycosylation would not be possible for these protein classes. 
A protein that was inserted post-translationally could then only be recognized by 
the OST isoform STT3B for N-glycosylation of these consensus sites. Thus, post-
translational N-glycosylation could occur either due to missed N-linked 
consensus sites during co-translational N-glycosylation, or due to post-
translational ER membrane insertion. 
 
Formation of the LLO and Congenital Disorders of Glycosylation 
Regardless of its utilization by OST STT3A or STT3B isoforms, the lipid-
linked oligosaccharide (LLO) goes through its own extensive synthesis before 
peptide attachment. Building from a dolichol (Dol) lipid base, monosaccharides 
(for eukaryotes, this is a combination of GlcNAc, mannose, and glucose) are 
subsequently added by formation of glycosidic bonds performed by an ordered 
series of saccharide specific enzymes ultimately creating a final branched chain 
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of oligosaccharides (Figure I-7) [1]. The first seven saccharides are added in the 
cytosol. After a fifth mannose addition to create Man5GlcNAc2-PP-Dol, the 
enzyme Rft1 flips the LLO precursor into the ER lumen (classified as a flippase). 
Once inside, an additional four mannoses are added followed by three glucoses 
to create the completed LLO donor Glc3Man9GlcNAc2-PP-Dol [51]. 
In the LLO synthesis pathway there are many identified mutations (42 
currently known) in the genes encoding enzymes required for both LLO synthesis 
and LLO transfer to the peptide that lead to congenital disorders of glycosylation 
(CDGs) type I (Figure I-7) [52]. Recently, the first CDG causing mutations have 
been identified in the STT3A and STT3B catalytic subunits of the mammalian 
OST [53].  Patients with a homozygous point mutant and a homozygous intronic 
mutant resulted in decreased levels of STT3A or STT3B respectively, and 
presented with hypoglycosylation of a number of substrates. Additionally, defects 
in glycan trimming and processing enzymes, monosaccharide transporters, or 
essential structural proteins to the pathway are also associated with CDGs (CDG 
type II) [52]. Most of these are found farther along the secretory pathway in the 
Golgi apparatus, but a few have been identified in ER processing steps (see next 
section). 
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Figure I-7. Formation of the lipid-linked oligosaccharide (LLO). LLO 
formation begins in the cytosol by the addition of two N-acetylglucosamine 
(GlcNac) monosaccharides to a dolichol precursor. UDP (or UMP for the first 
GlcNAc) is released in the process. Five mannose (Man) monosaccharides are 
then added in a branching formation. The integral protein Rft1 flips this complex 
into the ER lumen, where more mannose monosaccharides are added followed 
by three terminal glucose (Glu) monosaccharides. The monosaccharides are 
brought into the ER lumen by dolichol flipping. Enzymes catalyzing the addition 
of each monosaccharide attachment step are indicated. Those in red have 
known mutations that lead to CDGs. 
 
Schematic generated by H. Malaby. 
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N-glycosylation in protein folding and trafficking 
 Once an N-glycan is attached to a peptide, a series of glycan truncations 
are performed to direct chaperone activity and to insure that properly folded and 
assembled glycoproteins traffic outside of the ER while off pathway proteins are 
relegated to ER associated degradation (ERAD) (Figure I-8) [3,54]. First, the 
glucose trimming enzymes glucosidase I and II sequentially remove the two 
terminal glucoses, resulting in a single glucose remaining on the oligosaccharide. 
This specific glycan complex, Glc1Man9GlcNAc2, is a substrate for the ER 
resident protein folding chaperones calnexin (membrane bound) and calreticulin 
(soluble) and is recognized by their carbohydrate-binding globular domains [55]. 
A disulfide isomerase, ERp57, is also known to catalyze disulfide bond formation 
and associate with calnexin and calreticulin [56]. Once the glycoprotein is 
released from the protein folding chaperone, glucosidase II then trims off the last 
glucose, resulting in a Man9GlcNAc2 glycan. If this protein is folded properly, ER 
mannosidase I removes several mannoses from the glycan, allowing the 
glycoprotein to be recognized for transport in COPII coated vesicles to the Golgi 
apparatus [54]. How a glycoprotein is recognized as being properly folded and 
the exact mechanism of mannose-trimmed glycoprotein recognition for forward 
trafficking is not fully understood. 
 Some glycoproteins, however, are not fully folded after a single session 
with the chaperones and require further assistance. These proteins are 
recognized by UDP-glucose:glycoprotein glucosyltransferase (UGGT); the UGGT 
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Figure I-8. N-linked glycosylation and protein folding in the ER. After a 
glycan is attached to a peptide, glucosidase I and II trim the first and second 
glucose residues, respectively. This glycan structure (Glc1Man9GlcNAc2) is a 
specific substrate for the ER folding chaperones calnexin (pictured) and 
calreticulin. ERP57 aids in disulfide bond formation. Once the peptide is 
released, glucosidase II trims the remaining glucose creating Man9GlcNAc2. If the 
protein is folded correctly, several mannose resides are trimmed by mannosidase 
I and are recognized for forward trafficking and ER exit. If the peptide is not 
folded correctly, UGGT reattaches a glucose residue making the peptide a 
substrate for ER folding chaperones once again. If a peptide remains stuck in this 
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folding cycle, it is sequestered by ERAD macherinery (OS-9) and transported 
outside the ER via Hrd1 and Sel1 for degradation by the proteasome. 
Glucosidase I and mannosidase I both have known mutations that lead to CDGs. 
 
Schematic generated by H. Malaby. 
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N-terminal domain binds the unfolded peptide and the UGGT C-terminal domain 
catalyzes the readdition of glucose to the terminal position on the glycan [57,58]. 
This once again allows the glycoprotein to be recognized as a substrate by 
calnexin and calreticulin. This cycle will continue until either 1) the glycoprotein is 
properly folded and forward trafficking can occur, or 2) the glycoprotein is 
sequestered by ERAD. It has been proposed that trimming of terminal mannose 
residues acts as a molecular timer limiting glycoprotein presence in the folding 
cycle, although this has not been fully elucidated [3]. It is known that ER resident 
lectins OS-9 and XTP3-B recognize trimmed ERAD substrates by their mannose-
6-phosphate receptor homology (MRH) domains [59]. OS-9 and XTP3-B then 
target these substrates to retrotranslocation machinery in the ER membrane 
(Sel1 in the Hrd1 complex), where peptides are moved into the cytosol for 
ubiquitination and proteasome degradation [3]. 
 Interestingly, the OST enzymatic isoform STT3B has been implicated in 
ERAD by marking unfolded proteins for degradation through glycosylation of 
consensus sites that normally are buried in a natively folded protein [43]. This 
finding resonates well with the known role of post-translational N-glycosylation, 
which serves to find and glycosylate unoccupied, recognizable consensus sites 
after translation is completed [30]. 
 While there are exceptions to protein targeting for ERAD (not all proteins 
targeted for destruction are glycoproteins and thus there must be other 
recognition mechanisms for degradation that do not involve lectins [60]), all 
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proteins that have an attached N-glycan are recognized by the folding and 
assembly machinery and are required to undergo correct folding regulated by 
glycan trimming for forward trafficking to occur. Thus, it is essential for 
glycoproteins to not only have an intact N-linked consensus site, but also to have 
a high rate of N-glycan occupancy [61]. 
 
Previous primary sequence trends in N-linked consensus sites 
 Whether an N-glycan is attached by co-translational or post-translational 
N-glycosylation, the consensus sequence for attachment is the same: N-(X)-T/S-
(Y), where X and Y can be any amino acid other than proline. Using 
computational and in vitro approaches, several trends in N-linked glycosylation 
consensus sites have been noted. 
 The first study on the N-glycosylation consensus sequence examined a 
number of known glycoproteins and determined that a tripeptide sequence of 
NXT/S is necessary for N-glycosylation [62]. Several in vitro studies have since 
found that threonine residues in the consensus site result in more glycosylated 
protein than serine residues in peptides translated for a similar time period 
[63,64]. By adding short peptides containing NXT, NXS, or NXC sites to calf liver 
microsomal membranes with 14C radiolabeled GlcNAc and tracking the 
incorporation of the radioactive N-glycan over 30 minutes, it was found that 
threonine consensus sites incorporated glycans about 40 times faster than serine 
consensus sites [63]. Cysteine consensus sites were 2.5 times slower than 
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serine; so slow that at steady state NXC sites are mostly unglycosylated and are 
found so infrequently that they are often, including here, left out of the NXT/S 
consensus sequence. These results were repeated two decades later, this time 
including non-physiological analogues of threonine. Again, threonine produced 
the fastest kinetics by a large margin. Threonine analogues were not supported 
in the hydroxyl residue consensus site position [64]. 
The N-glycosylation efficiencies of consensus sites with varying amino 
acids in the X position has also been studied using a similar 14C radiolabeled 
LLO. Using short peptides containing NXT consensus sites, it was discovered 
that proline is not tolerated in the X position [65], or in the amino acid 
immediately following the hydroxyl residue (the Y position) [66]. This proline 
intolerance can now be explained by the structure of the peptide binding site in 
the OST homolog PglB since proline would kink the peptide to such an extent 
that favorable confirmation is impossible for both hydroxyl residue coordination 
and asparagine activation [25]. 
Other studies have also observed the role the X residue plays on the 
efficient production of glycoprotein [67,68]. Using the rabbit reticulocyte in vitro 
translational approach, a peptide consensus sequence library was translated to 
determine N-glycan attachment efficiency. From experiments given one hour for 
equilibrated translation, it was found that some X residues are much better than 
others in NXS consensus sites. Serine, cysteine, histidine, and threonine all 
produced robust glycopeptides, where as tryptophan, aspartate, glutamate, and 
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leucine were all poorly N-glycosylated. Interestingly, these X residue effects on 
N-glycosylation efficiency were diminished in an NXT site, where all amino acids 
(except proline) in the consensus site glycosylated proficiently [67]. 
Several studies have branched out of the immediate consensus site area, 
looking for more long-range effects on N-glycosylation [69,70,71]. Bacterial 
glycopeptides were found to require a negatively charged residue in the -2 
position upstream of the consensus site [70], and this has been attributed to a 
predicted salt bridge formation between the negatively charged residue in the 
peptide and an arginine in the PglB structure [25]. A computational study looking 
at 617 glycoproteins found a few trends in flanking consensus site residues, such 
as a slightly increased likelihood of a positively charged residue 5 residues 
upstream or hydrophobic residues 10-20 residues downstream of NXS 
consensus sites [71]. 
While many of these biochemical and computational findings have been 
immensely helpful and predictive, characterizing the N-glycosylation efficiencies 
for native consensus sites of physiologically relevant glycoproteins, and the roles 
of co- and post-translational N-glycosylation in the sequential context of these 
consensus sites, has yet to be fully elucidated. 
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The KCNE family of type I transmembrane peptides 
 Type I transmembrane glycopeptides can be a particularly powerful tool 
for studying the kinetics of N-glycosylation, as many of the peptides are small 
and expected to translate rapidly [72]. This rapid translation puts a significant 
time restraint on co-translational N-glycosylation, making these glycopeptides 
sensitive to factors that shift the balance of co- and post-translational N-
glycosylation. This thesis focuses on the heavily N-glycosylated KCNE family of 
type I transmembrane peptides as an ideal model to study the kinetics of N-
glycosylation. 
 
Discovery 
 The KCNE family consists of five members (KCNE1-KCNE5) that act as β 
accessory subunits essential for the modulation of voltage-gated potassium (K+) 
channels [73]. KCNE1 (E1) (also known as MinK, minimal K+ channel protein) 
was discovered in 1988 when fractionated mRNA was injected into Xenopus 
oocytes and was initially thought to be the pore forming K+ channel [74]. Almost a 
decade later, it was established that E1 is not in fact the K+ channel responsible 
for conductance, but rather an accessory peptide β subunit that preferentially 
assembles with a Xenopus oocyte native voltage-gated K+ channel, KCNQ1 (Q1) 
[75,76]. Through BLAST homology searches of EST databases, four other 
potential peptides were identified by sequence similarity. These MiRPs (MinK 
related protein) were designated MiRP1-4, but are now most commonly referred 
29
to as their gene names along with E1: KCNE2 (E2), KCNE3 (E3), and KCNE4 
(E4) and KCNE5 (E5) [77]. 
 
Structure and N-linked glycosylation consensus sites 
 As type I transmembrane peptides, the KCNE family is composed of an 
extracellular N-terminus, transmembrane domain, and cytosolic C-terminus. The 
KCNEs range in length from 103 (E3) to 177 (E4) residues, with variable length 
of the N- and C-termini (Figure I-9) [73]. All of the KCNEs contain an ER 
retention signal of three to four arginine and lysine residues immediately 
following the transmembrane domain, explaining the type I orientation and lack of 
forward trafficking unless assembled with a channel [78]. All of the KCNEs also 
contain at least one, and up to three, N-linked glycosylation consensus sites: E1 
contains two consensus sites starting at residues 5 (NTT) and 26 (NMS); E2 has 
two consensus sites located at residues 6 (NFT) and 29 (NTT); E3 has three 
consensus sites found at residues 5 (NGT), 22 (NAT), and 41(NQT); E4 has one 
consensus site at residue 8 (NST); and E5 has two consensus sites at residues 2 
(NCS) and 25 (NAS) [40]. 
The N-terminal, transmembrane, and C-terminal domains of KCNEs are 
thought to form α-helical sections based on circular dichroism (CD), nuclear 
magnetic resonance (NMR), and alanine/leucine scanning experiments 
[79,80,81,82]. However, only the transmembrane and C-terminal domains are 
implicated in K+ channel modulation [73,83,84,85]. 
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Figure I-9. The KCNE family. Cartoon depictions of the KCNE (E1-E5) family. 
Number of glycosylation sites are designated and consensus site sequences are 
shown. Blue residues indicate the beginning of the TM domain; red residues 
mark the last amino acid of the peptide. 
 
Schematic generated by H. Malaby. 
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KCNE Physiology 
 Members of the KCNE family have been shown to modulate a large 
number of voltage-gated K+ channels [73]; however, the only known K+ channel 
to readily assemble with all five KCNE members is KCNQ1 (Q1). Each Q1 
subunit contains six transmembrane domains (S1-S6) and cytosolic N- and C-
termini (Figure I-10A) [86]. Four homomeric Q1 subunits assemble to form a 
functional channel [87]. S1-S4 form the voltage sensing domain, and S4 contains 
several arginine residues responsible for outward movement that causes 
channeling opening upon depolarization [88]. S5-S6 form the pore region, 
through which a string of highly conserved residues among voltage-gated K+ 
channels, TVGYG, align such that the carbonyl backbones mimic the hydration 
shell of K+ ions to form the K+ selectivity filter [89,90,91]. Q1 contains a short N-
terminus with little known function, but a lengthy C-terminus with four α-helices 
containing multiple calmondulin binding motifs, phosphorylation sites for many 
kinases including PKC and Src Kinase, a binding site for the regulatory protein 
Yotiao, and several putative dimerization and tetramerization domains [86,92]. 
For both two-electrode voltage clamp (TEVC) utilizing Xenopus oocytes 
and whole-cell patch clamp performed on mammalian cells at physiological pH, 
Q1 expressed alone elicits rapid activation (equilibration reached within 1 sec), 
and undergoes inactivation upon depolarization (Figure I-10A) [86]. When E1 is 
expressed with Q1, a drastic change is observed that results in significant 
slowing of activation (over 4 sec for equilibration), increased current amplitude, 
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Figure I-10. KCNE modulation of the K+ channel KCNQ1. (A) One KCNQ1 
(Q1) subunit is composed of six transmembrane domains (S1-S6), where S4 is 
the voltage-sensing domain containing several Arg residues and S5 and S6 form 
the pore. Four subunits assemble into a complete channel. Q1 expressed alone 
opens rapidly as shown by a schematic of an electrophysiological trace where 
the channel is opened at various voltages ranging from -100 mV to +60mV for 2 
sec. (B) Electrophysiological traces of the KCNEs with Q1 under the same 
conditions as (A). All cartoons are approximations of well-documented, 
reproducible channel complex phenotypes [74]. 
 
Schematic generated by H. Malaby. 
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and loss of inactivation (Figure I-10B) [75]. In contrast, E2 expressed with Q1 
results in what is basically a leak channel – a linear voltage-current relationship, 
with instantaneous activation and deactivation (meaning the channel does not 
fully close at physiological equilibrium) [93]. Q1/E3 complexes are constitutively 
conducting leading to a linear voltage-current relationship (meaning the channel 
fully opens at all voltages, but remains closed in the absence of a charge 
differential) [94]. When Q1 coassembles with E4, current is severely reduced 
[95]. Q1/E5 complexes have similar biophysical properties as Q1/E1 with an 
activation threshold shifted to about +40mV and increased kinetics of channel 
closing [73,96]. Since physiological membrane potential of most cells is about -80 
mV, the Q1/E5 channel complex would only be functional after depolarization has 
occurred for sometime, otherwise E5 complexes would mostly be non-functional. 
There is also evidence that the KCNEs can form mixed heteromeric 
channel complexes [97]. E1 and E4 have been found to assemble with Q1 as 
one complex and present a conductance pattern that is a hybrid of Q1/E1 and 
Q1/E4 complexes [98]. Likewise, Q1/E1/E3 complexes have been detected, also 
presenting a blending of channel modulatory effects [99]. The possibility remains 
that other KCNE heteromeric complex combinations can occur and may play an 
instrumental role for in vivo electrochemical homeostasis. 
 A number of studies have been conducted utilizing cysteine cross-linking 
and chimeric constructs to determine KCNE residues important in modulation 
and to identify the location of the β subunit in the channel complex 
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[73,83,84,85,100]. From these findings, it is thought that the KCNEs could reside 
between the S5/S6 linker region and S4 in Q1, and that most if not all interaction 
with the channel is occurring in the transmembrane and C-terminal domains of 
the KCNE peptides [101]. 
 
Tissue expression 
 mRNA for all of the KCNEs has been detected readily throughout a 
number of mammalian tissues by RT-PCR [102]; however, KCNE protein 
detection has not been as efficiently cataloged. mRNA for all five KCNEs have 
been found expressed in cardiac tissue, however protein has only been detected 
for E1 (from human, horse, and guinea pig), E2 (human), and E3 (horse) 
[73,103,104]. Likewise, KCNE mRNA is often found throughout smooth muscle 
and epithelial tissues, including: small intestine (E1, E3, E4), stomach (E1, E2, 
E3), pancreas (E1, E3), kidney (E1-E4), lung (E1-E4), uterus (E1, E4), testis and 
ovaries (E1, E3), leukocytes (E1, E3), inner ear (E1), bladder (E2, E3), eye (E2), 
colon (E3), and trachea (E3) [102]. KCNE protein for smooth muscle and 
epithelial tissues has only been identified in the stomach (E1, E2), inner ear (E1), 
colon (E3) and small intestine (E3) [105,106,107,108]. Finally, KCNE mRNA in 
skeletal muscle has been found for E2, E4, and E5 and all KCNE mRNA are 
found in the central nervous system [102], but only E1 and E3 proteins have 
been detected in rat brain [109]. 
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 While much work has yet to be done on further identifying KCNE 
expression and particularly identifying KCNE protein in channel complexes in 
mammalian tissues, it is clear that the KCNEs are widely diverse and potentially 
fulfill a plethora of homeostatic roles. Amongst the tissues that the KCNEs are 
found, the system arguably the most sensitive to electrochemical fluctuations is 
cardiac tissue and it is here that the most well understood KCNE complex, 
Q1/E1, contributes to an essential function – the cardiac action potential [73]. 
 
The KCNE family and the cardiac action potential 
 The cardiac action potential consists of five distinct phases, numerically 
designated 0-4 (Figure I-11A) [110]. Phase 0 is the depolarization at the cell 
membrane caused in response to the rapid opening of voltage-sensitive Na+ 
channels. The repolarization phases 1-4 are contributed by distinctly identified 
currents whose timing is crucial for proper cardiac function. Phase 1 is 
associated with Ito K+ current, a rapidly activating current that is formed by Kv1.4, 
Kv4.2, or Kv4.3 (depending on the species) [111]. The plateau of phase 2 in the 
action potential is maintained by Ca2+ current and several minor K+ currents (IKp, 
IKsus, or IKur) possibly carried out by Kv1.5 or K2P [110]. Phase 3 is composed of 
delayed outward rectifying K+ currents (IKr and IKs) formed by hERG (human 
Ether-à-go-go Related Gene) and Q1/E1 respectively [75,76,112]. Lastly, phase 
4 is the initiation of the cardiac action potential and is mediated by inward 
rectifying K+ currents: IK1 (Kir 2.1-2.4), IKAch (Kir 3.1 and 3.4), and IKATP (KATP 
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Figure I-11. Conductance patterns of cardiac muscle. (A) A localized 
schematic of the cardiac action potential. Amount of current is shown as a 
function of time. Phases are indicated above and shaded for distinction. The 
predominant K+ currents associated with each phase are shown. (B) top 
Schematic of a normal electrocardiogram (ECG) for a healthy individual. Peak 
waves are labeled appropriately. bottom Schematic of an ECG for an individual 
with Long QT Syndrome (LQTS). 
 
Schematic generated by H. Malaby. 
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channels) [110]. Depolarization (phase 0) will occur again once a threshold 
potential is reached after the electrochemical gradient is restored. This 
restoration is assisted by a number of exchange pumps (Na+-K+ and Na+-Ca+) in 
addition to the inward rectifiers [113,114].  
While Q1/E1 is the only KCNE channel complex that has been identified in 
the cardiac action potential, the mRNA presence of the other KCNEs in cardiac 
tissue hints at larger roles for the KCNE family. Specifically, there has been 
debate and speculation over whether Q1/E2 also is part of IKs, and if hERG, 
which controls IKr, might be in complex with E2 as well [115,116]. Moreover, the 
existence of cardiac diseases that arise from mutation in the KCNEs 
[117,118,119] has lent stronger evidence for E1, E2, and E3 roles in the cardiac 
action potential. 
 
The KCNE family and disease 
 Many mutations have been identified in genes encoding cardiac ion 
channels that drastically alter the conductance pattern of the heart and lead to 
disease [117,119,120]. Inherited arrhythmias are most often found amongst the 
channels responsible for the essential timing of phase 3 of the cardiac action 
potential – the delayed rectifier channels hERG and Q1/E1 [117]. On a surface 
electrocardiogram (ECG), these mutants result in a prolongation of the QT 
interval (Figure I-11B), and thus their associated disease was named Long QT 
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Syndrome (LQTS) [120]. Patients with LQTS are predisposed to ventricular 
fibrillation, torsades de pointes arrhythmia, and sudden death [121]. 
 A large number of point mutations have been identified across all domains 
of Q1, hERG, E1, and E2 that result in LQTS [117]. In the KCNEs, most of these 
mutations are found in the transmembrane and C-terminal domains, regions 
already known to effect channel modulation and much work has been done to 
identify the exact biophysical cause of these disease mutants. Interestingly, there 
have also been several identified mutants in the N-terminus of E1 (T7I) [122] and 
E2 (T8A, Q9E) [77,123] that have no explainable cause since the N-terminus of 
KCNEs has not been found to effect modulation. In addition, a mutant in the N-
terminus of E3 (T4A) has recently been linked to Burgada Syndrome, another 
ECG irregularity appearing as malformed QRS peaks [124]. Interestingly, all of 
these mutations occur in or directly adjacent to N-glycosylation consensus sites. 
However, since all of these KCNEs have at least one additional consensus site 
that is potentially unaffected, it was unclear why these mutations were leading to 
disease. 
 The E1 T7I mutant was previously characterized and found that the 
ensuing LQTS is indeed due to an N-glycosylation deficiency [2]. It was 
discovered that the first consensus site in E1 (NTT) is a co-translationally N-
glycosylated site, while the second consensus site (NMS) is actually a post-
translationally N-glycosylated site (Figure I-12A). The N-glycosylation kinetics of 
E1 were not affected by co-expression with Q1 [2]. The LQTS mutant T7I 
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Figure I-12. Characterization of the E1 T7I mutation. (A) The first wtE1 N-
glycosylation consensus site (NTT) is co-translationally N-glycosylated while the 
second consensus site (NMS) is post-translationally N-glycosylated. (B) The E1 
T7I mutation destroys the first consensus site, leaving only the NMS site which is 
inefficiently post-translationally N-glycosylated and does not traffic to the cell 
surface. (C) A point mutant (E1 T7I S28T) converting the NMS site into an NMT 
site shifts the N-glycosylation kinetics of this peptide back to co-translational N-
glycosylation and forward trafficking is restored. 
 
Summary schematic generated by H. Malaby on findings from: T. Bas, G.Y. Gao, 
A. Lvov, K.D. Chandrasekhar, R. Gilmore, W.R. Kobertz, Post-translational N-
glycosylation of type I transmembrane KCNE1 peptides: implications for 
membrane protein biogenesis and disease, J Biol Chem 286 (2011) 28150-
28159. 
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eliminates the first consensus site such that the second post-translational N-
glycosylation site is the only site remaining (Figure I-12B). Although wild-type (wt) 
E1 efficiently traffics to the plasma membrane in the presence of Q1 [78], E1 T7I 
does not traffic despite co-expression of the channel. Surprisingly, it was 
discovered that if the second consensus site was converted from a NMS to a 
NMT site (E1 T7I S28T, Figure I-12C), this consensus site was switched from 
post- to co-translational N-glycosylation, and was again efficiently trafficked to 
the plasma membrane with Q1 [2].  
 Identifying primary sequence factors that can cause subtle shifts in N-
glycan attachment rates and have drastic effects on protein expression and 
function is a crucial topic of study which has yet to be fully explored. This thesis 
focuses on defining the N-glycosylation kinetics for the consensus sites in the 
KCNE family, and uncovering several new determinants that affect the 
distribution of co- and post-translational N-glycosylation for type I transmembrane 
peptides. 
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CHAPTER II: CHARACTERIZATION OF N-GLYCOSYLATION CONSENSUS 
SITES IN THE KCNE FAMILY 
 
Abstract 
 
Type I transmembrane peptides acquire N-linked glycans during and after protein 
synthesis to facilitate forward trafficking through the secretory pathway. 
Mutations in N-glycosylation consensus sites (NXT and NXS, where X ≠ P) that 
alter the kinetics of the initial N-glycan attachment have been associated with 
cardiac arrhythmias; however, the molecular determinants that define co- and 
post-translational consensus sites in proteins are not known. Here, we identified 
co- and post-translational consensus sites in the KCNE family of K+ channel 
regulatory subunits to uncover three determinants that favor co-translational N-
glycosylation kinetics of type I transmembrane peptides:  threonine containing-
consensus sites (NXT), multiple N-terminal consensus sites, and long C-termini. 
The identification of these three molecular determinants now makes it possible to 
predict co- and post-translational consensus sites in type I transmembrane 
peptides.  
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Introduction 
 
The folding, assembly, and trafficking of eukaryotic membrane proteins to 
the cell surface is highly dependent on asparagine-linked (N-linked) 
glycosylation. During membrane protein biogenesis in the ER, the 
oligosaccharyltransferase (OST) attaches a 14-sugar oligosaccharide to the 
nascent polypeptide at N-linked consensus sites: N-X-T/S-Y, where X and Y can 
be any residue other than proline [14,15]. Until recently, the initial attachment of 
N-linked glycans to polypeptides was thought to be exclusively a co-translational 
process; however, kinetic investigations have shown that post-translational N-
glycosylation occurs at select consensus sites in both water soluble [30,36] and 
membrane-embedded proteins [2,41,42]. Although either threonine or serine is 
required at the (n + 2) position [64], previous studies have shown that serine-
containing consensus (NXS) sites are less efficiently N-glycosylated than the 
analogous threonine-containing consensus (NXT) sites [63,67,68]. This 
difference in N-glycosylation efficiency has been attributed to the physiochemical 
differences of the serine and threonine hydroxyl groups; however, the recent 
crystal structure of a bacterial OST indicates that the hydroxyl residue is not 
directly involved in the catalytic transfer of the N-linked glycan to the asparagine 
residue [25]. Thus, the molecular and cellular bases for the serine and threonine 
differential remain unclear. 
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One family of membrane-embedded proteins that contain multiple serine 
and threonine N-linked glycosylation sites is the KCNE family of type I 
transmembrane peptides (E1 – E5) (Figure I-9). These N-terminally glycosylated 
membrane proteins co-assemble with and modulate several different voltage-
gated K+ channels [73]. Mutations that destroy N-linked glycosylation sites in E1 
and E2 give rise to Long QT syndrome (LQTS) [122,123], a disorder of the 
cardiac rhythm that is sometimes accompanied with neural deafness [125]. We 
have recently shown that the E1 LQTS mutant, T7I, is particularly deleterious 
because it prevents N-glycosylation at both consensus sites, yielding 
unglycosylated regulatory subunits that do not traffic to the cell surface [2]. This 
long range N-glycosylation defect occurs because direct ablation of one E1 
consensus site shifts the N-glycosylation kinetics from co-translational to post-
translational glycan attachment. Interestingly, the kinetics of N-glycan attachment 
could be converted to co-translational by simply switching the hydroxyl residue 
from serine to threonine in the remaining intact consensus site, rescuing both N-
glycosylation and the anterograde trafficking defect of the T7I mutation. 
Because N-glycosylation kinetics have been implicated in the diseases of 
the cardiac rhythm, we set out to identify co- and post-translational consensus 
sites in the KCNE family in order to define the molecular determinants that affect 
the kinetics of N-glycosylation in type I transmembrane peptides. Using rapid, 
radioactive pulse-chase experiments, we determined the N-glycosylation kinetics 
of wild type E2 – E5 and a panel of N-glycosylation mutants. By comparing the 
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N-glycosylation kinetics of the consensus sites in the KCNE family, we 
uncovered three determinants of N-glycan attachment to type I transmembrane 
peptides: (1) substituting serine for threonine in consensus sites significantly 
reduces co-translational N-glycosylation; (2) multiple consensus sites in the N-
terminus of a type I transmembrane peptide increase N-glycan attachment 
efficiency; (3) longer cytoplasmic C-termini favor co-translational glycosylation. 
The identification of these three determinants of N-glycan attachment provides a 
schema to predict the consensus sites in type I transmembrane peptides that are 
susceptible to the long-range glycosylation defects observed with the T7I LQTS 
mutation. 
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Materials and Methods 
 
Cloning and plasmids: Human KCNE1 – KCNE5 were cloned into 
pcDNA™3.1(-) vector such that five additional methionine residues and an HA tag 
(YPYDVPDYA) were added to the C-terminus of each KCNE peptide [2]. 
Mutations were introduced using either the Quikchange Site Directed 
Mutagenesis Kit or by traditional PCR cassette mutagenesis (Syzygy Biotech 
Taq 2x MeanGreen Master Mix) between the 5’ KpnI and 3’ BglII sites. Single N-
glycosylation consensus site constructs were generated by mutating the 
asparagine residue in the other consensus sites to glutamine (e.g. “E2 N6” 
contains a N29Q mutation).  All constructs were confirmed by DNA sequencing 
the entire gene.  
 
Cell culture and transfection: Chinese hamster ovary-K1 (CHO) cells were 
sustained in Gibco-F12K Nutrient Mixture, Kaighn’s Modification (with L-
glutamine) media, supplemented with 10% FBS (Sigma) and 1% 
penicillin/streptomycin. Cells were passaged using 0.5% Trypsin-EDTA and 
plated onto 20 mm dishes at 80% confluency. After 24 h, the cells were 
transiently transfected with a mixture of 3 µg KCNE DNA and 80 µL 
Lipofectamine in 2 mL OptiMem. After 6 h at 37°C, the transfection cocktail was 
removed, 10 mL of F12K media was added and the cells were incubated for 15-
20 h. 
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 Pulse-chase assays and cell lysis: Transfected cells were washed with PBS (2 
x 4 mL) and incubated for 35 min at 37°C in Gibco DMEM High Glucose Media 
(4.5 g/L D-glucose, lacking L-methionine and L-cysteine), supplemented with 
10% FBS, 1% Pen Strep, and 2 mM L-glutamine. The media was removed and 
the cells were incubated at 37°C for 2 min in (4 mL) of DMEM High Glucose 
Media containing 100µCi/mL EasyTag EXPRESS [35S] Protein Labeling Mix 
(Perkin Elmer). The radioactive media was removed and the cells washed with 
PBS (2 x 4 mL) and chased with F12K media for 3, 6, 9, or 12 min at 37°C. The 
cells were then washed with PBS (2 x 4 mL), and lysed with 750 µL of low salt 
lysis buffer (in mM): 50 TRIS-HCl, pH 7.4, 150 NaCl, 20 NaF, 10 Na3VO4, 1% 
NP-40, 1% CHAPS, which was supplemented with protease inhibitors: 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1µg/mL each of leupeptin, pepstatin, 
and aprotinin (LPA). Cells were lysed for 30 min with vigorous shaking at 4°C, 
and the cell debris scraped and pelleted at 14,000 rpm for 10 min at room 
temperature. 
 
Radioimmunoprecipitation and electrophoresis: Protein G agarose beads 
(Pierce) were prepared by washing (3 x 750 µL) in low salt lysis buffer. After 
pelleting the cell debris, the supernatant was precleared with 50 µL beads for 2 
hours at 4°C on a roller drum. The beads were then spun down, and the 
supernatant transferred to new tubes containing 25 µL beads pre-incubated with 
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1µL monoclonal anti-HA antibody (Sigma). After an overnight incubation at 4°C, 
the beads were pelleted, the supernatant removed and the beads were subjected 
to 5 washes: low salt lysis buffer (3 x 750 µL); high salt buffer (1 x 750 µL): 
50mM TRIS-HCl, pH 7.4, 500 mM NaCl, 1% NP-40, 1% CHAPS, 20 mM NaF, 10 
mM Na3VO4, and a final wash with low salt lysis buffer (1 x 750 µL). For 
enzymatic deglycosylation assays, 1 µL Endo Hf (New England Biolabs) was 
added to beads in 50 µL low salt lysis buffer and incubated at 37°C for 1 hour.  
Peptides were eluted from the beads with (50 uL) of 100 mM DTT and 2x SDS 
gel loading buffer at 55°C for 15 min. Samples were analyzed by SDS-PAGE 
(10% or 15%) and the gels were dehydrated for 1 h in a 30% Ethanol, 2% 
glycerol solution. Gels were dried for 2 h at 80°C, applied to film, and analyzed 
for autoradiography by Typhoon FLA-9000 phosphoimager after 7 – 14 d. 
 
Determination of co- and post-translational N-glycosylation: All signals were 
quantified using Image Gauge software (Fujifilm). For all constructs (except 
wtE3), the percent maximally glycosylated was calculated by dividing the signal 
of the maximally glycosylated species by the total signal at each time point. For 
the wtE3 constructs with three consensus sites, all glycoforms were used; thus, 
the percent glycosylated is the sum of the signal from all three glycoforms divided 
by the total signal at each time point. The total glycosylation in Table 1 is the 
maximally glycosylated species at 12 min except for the triply glycosylated 
constructs, where all three glycoforms were used. To determine the percent co-
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translational N-glycosylation for each construct, we divided the percent 
glycosylated at 0 min (co-translational) by the 12 min time point (total 
glycosylation). This simplified calculation assumes that the small KCNE peptides 
are fully synthesized before the 3 min chase point and that the kinetics of co- and 
post-translational N-glycosylation are substantially different, both of which have 
been previously substantiated in the literature [2,30,126]. The percent post-
translational glycosylation was calculated by taking the difference between co- 
and total glycosylation and dividing it by total glycosylation for each construct.  
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Results 
 
N-glycosylation of the N-terminus of type I transmembrane peptides 
occurs within seconds to minutes upon insertion into the ER lumen [2]. To 
observe these rapid kinetics in radioactive pulse-chase experiments requires 
extremely short (2 min) pulses of [35S] methionine and cysteine. However, this 
experimental time constraint significantly reduces the amount of metabolically-
labeled protein that can be isolated by immunoprecipitation. Therefore, we 
sought experimental conditions that would allow us to observe and compare the 
kinetics of N-glycosylation of wild type and a panel of mutant KCNE peptides. 
Because both OST isoforms are conserved in all metazoans except 
Caenorhabditis [14], any readily transfectable cell line is sufficient as long as 
exogenous expression of the KCNE peptide does not deplete cellular substrates 
or saturate the ER machineries in the cell. Therefore, we chose to heterologously 
express the different KCNE constructs in CHO cells, which we have previously 
shown are not overwhelmed by exogenous expression of type I transmembrane 
peptides [2]. In addition, the subsequent Golgi modifications in CHO cells mirrors 
both the N- and O-glycosylation of E1 observed in cardiomyocytes [127] where 
all five KCNE peptides are expressed [102,103]. To increase and normalize the 
radioactive signal in our experiments, we used methionine-rich constructs that 
contained five methionine residues and an HA-tag (for immunoprecipitation) at 
the C-terminus of each KCNE peptide. Together, these experimental conditions 
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yielded enough metabolically labeled KCNE protein to observe co- and post-
translational N-glycosylation (Figure II-1). 
Using this experimental paradigm, we first examined wild type E4 (wtE4), 
which contains a single NXT consensus site (N8, T10) in its N-terminus (Figure 
II-2). Cells were metabolically labeled with [35S], chased with cold media, and the 
wtE4 proteins were isolated at various times (0 – 12 min). For every time point, 
two closely spaced bands were observed (Figure II-2A). Endo H treatment (which 
removes immature N-glycans found in the ER) of the 12 min sample resulted in a 
single, darker band that identified the upper and lower bands as glycosylated and 
unglycosylated protein, respectively (Figure II-2A, wtE4: EH lane). Time points 
were limited to 12 min because longer chase times resulted in further glycan 
processing, which changed the mobility and decreased the signal of the 
glycosylated species (data not shown). Plotting the data (Figure II-2B) showed 
that the amount of glycosylated material slowly increased over the entire time 
course. As expected, we observed similar results in other cell lines (Figure II-3).  
To calculate the amount of co- and post-translational N-glycosylation, we 
exploited the kinetic difference between these two unique mechanisms of N-
glycan attachment (Figure I-5). Although both modes of N-glycan attachment are 
rapid, post-translational N-glycosylation is substantially slower than co-
translational [2,30]. This kinetic disparity allows for a simplified convention where 
co-translational is defined as N-glycan attachment occurring during the 
radioactive pulse (zero time point) and all subsequent N-glycosylation during the 
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Figure II-1. Experimental design for pulse-chase assay with the KCNE 
family. Upper left: A KCNE construct (with 5 extra methionines and an HA tag) is 
expressed in CHO cells. On the pulse-chase day, cells are starved for 30 
minutes to deplete cellular methionine and cysteine which stops translation, 
pulsed for 2 minutes in media containing 35S methionine and cysteine, and 
chased from 0-12 minutes at 3 minute intervals. Several purification steps are 
performed as outlined in the Material and Methods section. A pulse-chase result 
is shown for wtE1. Each band per lane shows a different glycan species. To 
graph the data, the maximally N-glycosylated species is quantified and graphed 
as a percentage of total protein per time point. The N-glycosylation kinetics can 
further be divided by co- (0 minute glycosylation) and post (12 minute - 0 minute 
glycosylation) contributions. 
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Figure II-2. N-glycosylation kinetics of E4 reveals a threonine preference for 
co-translational glycosylation. (A) Cartoon of E4 N-terminus depicting the 
consensus site and representative fluorographs of wild type (wtE4: filled circles) 
and mutant (T10S: open circles) E4. Cells were pulsed for 2 min and chased for 
the indicated times.  Immunoprecipitated E4 proteins were separated by 
electrophoresis and detected by autoradiography. EH denotes the 
endoglycosidase H treated sample to identify the unglycosylated species. 
Unglycosylated (0-Gly) or singly glycosylated (1-Gly) are labeled. (B) Plots of the 
maximally glycosylated (1-Gly) species at each time point. The visible error bars 
that protrude beyond the data points are ± s.e. from 3 – 4 experiments. Co- and 
post-translational glycosylation percentages are shown for wtE4. 
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Figure II-3. N-glycosylation kinetics of threonine and serine sites are similar 
in different mammalian cell lines. (A) Representative gels of E4 T10 and T10S 
constructs expressed in CHO (top), HEK (middle), and HeLa (bottom) cells. (B) 
Plots of the maximally glycosylated species (1-Gly): E4 T10 (top); E4 T10S 
(bottom). Error bars are ± s.e. from 3-4 experiments; no error bars indicate n = 1.  
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chase periods as post-translational (see Experimental). Using this convention, 
only 16% of the N-glycosylated E4 protein is post-translationally glycosylated 
(Figure II-2B); thus, the NXT site in wtE4 is a strong co-translational site. 
Because wtE4 contains an NXT site, we compared its N-glycosylation kinetics to 
the T10S mutant (NXS site). In stark contrast to wtE4 (Figure II-2A), the majority 
of the T10S mutant protein was unglycosylated after the radioactive pulse (0 
min). After 12 min, however, the amount of N-glycosylated material nearly 
doubled, resulting in 50% post-translational glycosylation of the T10S mutant 
(Table II-1). These results with E4 show that the hydroxylated residue in the 
consensus site strongly influences the kinetics of N-glycosylation. 
We next determined the N-glycosylation kinetics of E2 because it has two 
NXT consensus sites (N6, T8 and N29, T31). Similar to the singly-glycosylated 
E4 construct, the NXT sites in wtE2 were co-translationally N-glycosylated 
(Figures II-4A and II-4C). Endo H treatment identified the unglycosylated and 
glycosylated bands, which was confirmed as the doubly glycosylated species 
when we examined the NXS mutants (T8S and T31S). Both NXS mutations 
reduced the amount of co-translational N-glycosylation, resulting in the 
appearance of a singly glycosylated species. Although the consensus site 
mutations were identical (threonine to serine), the reduction of co-translational N-
glycosylation compared to wtE2 was different for the two mutants. Therefore, we 
examined the E2 consensus sites individually using singly glycosylated 
constructs (Figures II-4B and II-4D). The N-glycosylation kinetics at N6 was 
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% Total % Co- % Post- 
E4 
wt 68.6 ± 3.9 83.6 ± 7.0 16.4 ± 7.7 
T10S 44.2 ± 1.3* 49.9 ± 4.5* 50.1 ± 5.3* 
E4 (XS) 78.0 ± 1.0 50.1 ± 1.3* 49.1 ± 1.8* 
E2 
wt 92.9 ± 2.0 82.1 ± 5.9 17.9 ± 6.0 
T8S 69.5 ± 2.7* 64.1 ± 3.6* 35.9 ± 4.9* 
T31S 38.4 ± 1.1* 65.3 ± 3.7* 34.7 ± 4.3* 
N6, T8 92.5 ± 2.5 80.5 ± 3.7 19.5 ± 4.1 
N6, T8S 59.0 ± 1.2* 52.5 ± 5.4* 47.5 ± 5.7* 
N29, T31 82.8 ± 1.6 71.0 ± 1.8 29.0 ± 2.3 
N29, T31S 10.5 ± 1.8* ND ND 
E5 
wt 71.4 ± 1.0 79.0 ± 2.8 21.0 ± 3.0 
S4T 70.9 ± 2.5 81.8 ± 3.2 18.2 ± 3.9 
S27T 74.2 ± 2.8 79.0 ± 3.6 21.0 ± 4.3 
N2, S4 83.4 ± 2.0 72.5 ± 2.3 27.5 ± 2.9 
N2, S4T 86.5 ± 0.7 77.4 ± 3.7 22.6 ± 3.7 
N25, S27 86.4 ± 0.8 67.0 ± 1.8 33.0 ± 2.0 
N25, S27T 86.7 ± 1.1 80.7 ± 2.8* 19.3 ± 2.9* 
E3 
wt# 40.6 ± 2.1 63.4 ± 7.6 36.6 ± 8.8 
wt (XL)#  58.2 ± 2.0* 87.4 ± 4.8* 12.6 ± 5.1 
N5 30.3 ± 3.8 30.1 ± 8.1 69.9 ± 16.9 
N5 (XL) 38.2 ± 1.0* 61.8 ± 3.5* 38.2 ± 4.2* 
N22 33.7 ± 2.2 43.4 ± 3.3 56.6 ± 7.5 
N22 (XL) 56.0 ± 2.7* 75.8 ± 6.2* 24.2 ± 7.1* 
N41 37.4 ± 5.1 14.2 ± 6.0 85.8 ± 18.8 
N41 (XL) 30.6 ± 0.2 71.4 ± 4.6* 28.6 ± 4.6* 
 
 
 
Table II-1.  KCNE N-glycosylation. Total glycosylation determined from the 
maximally glycosylated species at the concluding chase time point #except 
for the wtE3 and wtE3 (XL) constructs where all three glycoforms were 
used.  The percentages of co- and post-translational N-glycosylation were 
determined as described in the Experimental section.  Values are mean ± 
s.e. from 3 – 5 pulse-chase experiments.  ND, not determined; *, p < 0.05 
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(one-way ANOVA with a Tukey’s multiple comparison test).  Comparisons 
were performed for each KCNE member and only between constructs with 
the same consensus sites.   
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Figure II-4. Multiple consensus sites enhance N-glycosylation of E2. (A) 
Cartoon of E2 N-terminus depicting the consensus sites and representative 
fluorographs from pulse-chase experiments of wild type (wtE2: filled circles) and 
serine mutants (T8S: right-filled circles; T31S: left-filled circles). EH designates 
endoglycosidase H treated lane. (B) Representative pulse-chase results for the 
singly glycosylated constructs. Top panels: N-glycosylation kinetics at the first N-
glycosylation consensus site (N6) containing a threonine (T8: closed squares) or 
serine (T8S: open squares). Bottom panels: N-glycosylation kinetics at the 
second N-glycosylation consensus site (N29) containing a threonine (T31: closed 
triangles) or serine (T31S: open triangles). Unglycosylated (0-Gly), singly (1-Gly) 
and doubly glycosylated (2-Gly) species are labeled in the fluorographs where 
detected. (C, D) Plots of the of maximally glycosylated species from A: 2-Gly; B: 
1-Gly. Error bars are ± s.e. from 3 experiments.  
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nearly identical to wtE2 with a ~ 30% loss in co-translational and concomitant 
increase in post-translational glycosylation when the native threonine was 
mutated to serine (Table II-1). In contrast, the threonine to serine mutation at N29 
was more detrimental in the singly glycosylated construct—essentially inhibiting 
both co- and post-translational N-glycosylation even though a bona fide 
consensus site was present. Thus, the co-translational efficiency of NXS sites 
also depends on their location in the N-terminus. Moreover, these results with the 
singly glycosylated constructs (Figure II-4B) revealed a second determinant of N-
glycan attachment to type I transmembrane peptides: multiple consensus sites 
increase co-translational glycosylation efficiency.   
In contrast to E2, E5 contains two NXS consensus sites (N2, S4 and N25, 
S27). Surprisingly, these consensus sites in wtE5 were co-translationally N-
glycosylated (80%), yielding only two bands that were confirmed as 
unglycosylated and doubly glycosylated using Endo H (EH lane) and the singly 
glycosylated E5 mutants (Figure II-5A).  Moreover, conversion of either 
consensus site into an NXT site had no effect on the glycosylation kinetics. 
Because the multiple glycosylation sites in wtE2 partially masked the effect of 
threonine to serine mutation, we compared the glycosylation kinetics at the two 
E5 consensus sites separately (Figures II-5B and II-5C). Using these singly 
glycosylated E5 constructs, we observed a small, but significant increase in co-
translational N-glycosylation for the N25 consensus site when it was converted to 
NXT. Post-translational N-glycosylation varied between 20 – 35% for the E5 
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Figure II-5. Consensus site coupling in E5 obscures a mild co-translational 
preference for threonine. (A) Cartoon of E5 N-terminus depicting the 
consensus sites and representative fluorographs from pulse-chase experiments 
of wild type (wtE5: open circles) and threonine mutants (S4T: left-filled circles; 
S27T: right-filled circles). The maximally glycosylated species (2-Gly) is plotted 
on the right.  Co- and post-translational N-glycosylation at the (B) N2 and (C) 
N25 consensus sites. Left panels: Representative fluorographs of the NXS (S4: 
open squares; S27: open triangles) and NXT (S4T: closed squares; S27T: closed 
triangles) consensus sites. Right: Plots of the of maximally glycosylated species 
(1-Gly).  Unglycosylated (0-Gly), singly (1-Gly) and doubly glycosylated (2-Gly) 
species are labeled in the fluorographs where detected. Error bars are ± s.e. 
from 3 – 5 experiments. 
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single consensus site mutants (Table II-1), with the N25, S27 site (Figure II-5C) 
showing the most N-glycan attachment after protein translation. These results 
showed that the N-glycosylation kinetics are affected by the serine to threonine 
mutation; however, the measured effects were modest because the wild type 
NXS sites in E5 are efficiently co-translationally N-glycosylated. 
Lastly, we examined E3, which is the smallest of the KCNE peptides (103 
aa), yet it contains the most N-glycosylation sites (Figure I-9, NXT: N5, N22 and 
N41). Despite having three NXT sites, wtE3 is a poor substrate for N-
glycosylation (Figure II-6A), with over half of the metabolically-labeled protein 
remaining unglycosylated after 12 min. Of the N-glycoforms (confirmed by Endo 
H, Figure II-7), only the singly and doubly glycosylated species were observed at 
early time points. Subsequent post-translational N-glycosylation significantly 
increased the amount of the doubly glycosylated form; however, very little fully 
glycosylated material was observed. To determine whether one or more of the 
consensus sites were refractory to N-glycosylation, we compared the 
glycosylation kinetics of the single site mutants. Similar to wtE3, all three single 
site constructs were poor substrates for co-translational N-glycosylation (Figures 
II-6A and II-6B: open symbols) and thus the majority of the glycans were added 
post-translationally.  
The paucity of co-translational N-glycosylation for all of the NXT 
consensus sites in E3 suggested that another factor was influencing the N-
glycosylation kinetics. For type I transmembrane peptides, the length of the C-
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Figure II-6. C-terminal tail length affects E3 N-glycosylation kinetics. (A) 
Representative fluorographs from pulse-chase experiments. Top panels: wild 
type (wtE3: open circles) and the single glycosylation site mutants (N5: open 
squares; N22: open triangles: N41 open diamonds); Bottom panels: C-terminal 
elongation (XL) of the above constructs via an E3/E4 chimera (filled symbols).  
(B) Plots of (left) the glycosylated material (1-Gly, 2-Gly, and 3-Gly forms) for the 
wtE3 constructs and (right) maximally glycosylated species (1-Gly) of the single 
site mutants. (C) Representative fluorographs from pulse-chase results for a C-
terminal shortened E4 construct (XS). wtE4 data from Figure 2 are shown for 
comparison. (D) Percent co-translational N-glycosylation (zero time point) of the 
wild type and altered tail length forms. wt:  solid bars; XL and XS: hatched bars; 
*p < 0.05, unpaired two-sided Student’s t test; error bars in panels B and D are ± 
s.e. from 3 – 4 experiments. Cartoon of the E3 N-terminus depicting the three 
consensus sites.  
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Figure II-7. Identification of unglycosylated and glycosylated E3 bands. For 
wtE3, endoglycosidase H treatment of wtE3 identified the unglycosylated band, 
which confirmed that the four bands were 0 – 3-Gly. For wtE3 (XL), a singly 
glycosylated XL construct (N22 (XL)) was run alongside the wtE3 protein to 
identify the different glycoforms. 
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terminus should affect co-translational N-glycosylation because longer C-termini 
will increase both the probability of insertion into the Sec61 complex (translocon) 
by the signal recognition particle (SRP) complex and the time the peptide spends 
in the translocational tunnel [8]. Our results with E3 are consistent with this 
hypothesis because it has the shortest C-terminus (23 aa). Therefore, we made 
chimeras with E4 (which has the longest C-terminus) to determine whether co-
translational N-glycosylation of the NXT sites in E3 could be improved. In both 
the wild type and single site constructs, extending the length of the C-terminus 
(XL constructs) significantly increased the amount of co-translational and total N-
glycosylation for all consensus sites except N41, which had comparable amounts 
of total glycosylation (Figures II-6A and II-6B: closed symbols). The 
unglycosylated and differently glycosylated bands were identified by comparing 
gel mobilities to a singly-glycosylated construct (Figure II-7). For the wtE3 
construct, the improvement in N-glycosylation also reduced the amount of 
unglycosylated protein and increased the fully glycosylated form such that it and 
the doubly glycosylated species were the predominant glycoforms after 12 min. 
To confirm that the length of the C-terminus influences the kinetics of N-
glycosylation, we also made and examined the reverse E4/E3 chimera (XS), 
which has a shorter C-terminus than wtE4 (Figure II-6C). As expected, 
shortening the E4 C-terminus reduced the amount of co-translational N-
glycosylation, resulting in an increase in post-translational N-glycosylation 
(Figure II-6D). In total, these results demonstrated that co-translational N-
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glycosylation efficiency depends on the length of the C-terminus in type I 
transmembrane peptides.  
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Discussion 
 
Using rapid radioactive pulse-chase experiments to measure the kinetics 
of N-glycosylation, we determined that the consensus sites in E4, E2, and E5 
peptides are efficiently co-translationally N-glycosylated. In contrast, all three 
consensus sites in E3 are predominately post-translationally N-glycosylated.  
From these results, we identified three determinants of N-glycosylation kinetics 
for type I transmembrane peptides:  
The hydroxyl residue in the consensus site (NXT vs NXS). Our results 
show that substituting serine for threonine in co-translational sites significantly 
reduces co-translational and overall efficiency of N-glycosylation (Figures II-2 
and II-4). A threonine preference has been previously observed in vitro with 
hexapeptides, where a threonine to serine substitution results in a 40-fold 
decrease in N-glycan attachment [63]. Although we observed a threonine 
preference for co-translational N-glycosylation with type I transmembrane 
peptides, a similar preference has not been observed with water soluble proteins 
[30]. This discrepancy can be attributed to the insertion mechanism of type I 
transmembrane peptides into the ER translocon (Sec 61) [8]. For type I 
transmembrane peptides, the N-terminal N-linked consensus sites are inserted 
into the ER lumen en masse after the transmembrane domain exits the ribosomal 
tunnel (Figure I-2). Thus, the lifetime of the type I transmembrane peptide in the 
translocon, as well as the time the OST has to modify the NXT and NXS 
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consensus sites, is dictated by the length of the C-terminus (Figure I-9). Because 
the KCNE family of peptides has relatively short C-termini (~ 20 – 120 aa), the 
OST’s preference for NXT sites becomes evident, resulting in skipped NXS sites 
that are subsequently modified by the post-translational machinery, which was 
recently identified as the OST isoform STT3B [30] (Figure I-5). Recently, a 
hydroxyl residue preference was also discovered for type II transmembrane 
proteins [42], indicating that an NXT preference may be general for all single 
pass transmembrane proteins.  Although a threonine in the consensus site 
increases co-translational N-glycosylation, not all NXS sites are poor co-
translational sites.  Both NXS sites in wtE5 (Figure II-5) and the E1 N-terminal 
consensus site (Figure II-8) are co-translationally glycosylated. 
Multiple Consensus Sites. In addition to a threonine preference, N-glycan 
attachment is more efficient with type I transmembrane peptides that have 
multiple consensus sites (Figure II-4). The direct ablation or partial reduction of 
co-translational N-glycosylation at one site (T8S and T31S E2 mutants) leads to 
the appearance of unglycosylated material that may or may not (N29, T31S) be 
post-translationally glycosylated. For wtE5, this coupling effect between 
glycosylation sites overrides the threonine preference (Figure II-5A), yielding the 
same amount of glycosylated protein regardless of the hydroxyl groups in the 
consensus sites.   
Length of C-terminus. By manipulating the number of amino acids in the 
E3 and E4 C-termini, we also showed that co-translational N-glycosylation 
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Figure II-8. Examination of the E1 N5 consensus site shows no hydroxyl 
preference.  (Left) Cartoon of the E1 N-terminus. (Center) Pulse-chase results 
for the first E1 glycosylation consensus site, N5, which lacks the second site at 
N26: NXT, solid squares; NXS, open squares. (Right) The maximally 
glycosylated species (1-Gly) of the T7 and T7S constructs was plotted for each 
time point. Error bars are ± s.e. from 3 experiments.   
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efficiency is dependent on the length of the C-terminus. Elongation of a short C-
terminus can increase co-translational efficiency by two mechanisms. The first 
mechanism, as mentioned above, simply involves increasing the resident time of 
the type I transmembrane peptide within the ER translocon (Sec 61) by 
increasing the time it takes for the translocon-docked ribosome (Figure I-1A) to 
complete protein translation. The second mechanism involves the initial insertion 
of the type I transmembrane domain into the ER membrane. For KCNE peptides 
with relatively longer C-termini, the bolus of N-glycosylation at the zero time 
points indicates that the transmembrane domain of these peptides is recognized 
by the SRP and delivered and inserted into the ER translocon before protein 
translation is complete [8]. However, for wild type E3 peptides with extremely 
short C-termini (23 aa), the reduced amount of co-translational and total N-
glycosylation hints that these peptides may not enter the ER membrane via the 
translocon, but may instead be inserted by a post-translational ER translocation 
mechanism [44]. Thus, elongation of the E3 C-terminus may increase co-
translational N-glycosylation by improving insertion into the ER translocon. To 
perform our pulse-chase studies (Materials and Methods), the C-terminus of all 
constructs were actually 18 aa longer; therefore, for true wild type E3—which is 
N-glycosylated [128]- the likelihood for co-translational N-glycosylation is greatly 
diminished.  
 Because the insertion mechanism of single pass TM peptides into the 
translocon dictates how N-glycosylation sites enter the ER lumen, these three 
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determinants of N-glycosylation kinetics should be general for all type I 
transmembrane peptides that lack a cleavable ER signal sequence. A re-
examination of the KCNE family using these three determinants also reveals how 
the individual family members are designed to achieve maximal N-glycosylation.  
The majority of the consensus sites in KCNE peptides contain a threonine 
residue, which are readily co-translationally modified. Because the attachment of 
one N-glycan enhances subsequent modifications, all human KCNE peptides 
except E4 contain at least two consensus sites. For E4, its elongated C-terminus 
increases co-translational N-glycosylation, which alleviates the need for 
consensus site coupling. Conversely, E3 has three consensus sites to 
compensate for its extremely short C-terminus. Thus, the KCNE peptides are 
genetically-encoded to ensure that their N-termini are N-glycosylated.  
Although KCNE peptides are optimized to acquire N-glycans early and 
often during biogenesis to promote assembly and anterograde trafficking with K+ 
channel subunits [78], mutations can derail the process, leading to un- and hypo-
glycosylated proteins. We have previously shown that the inherited LQTS 
mutant, T7I, exposes a flaw in E1, where direct ablation of one consensus site 
indirectly reduces N-glycosylation at the remaining NXS site, resulting in 
unglycosylated E1 protein [2]. The determinants of N-glycosylation in this study 
directly explain this observation with E1—the ablation of one consensus site 
eliminates consensus site coupling, leaving a lone NXS site that is neither co-
translationally or post-translationally N-glycosylated. This compounded 
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hypoglycosylation was recapitulated with the N29, T31S E2 mutant in this study 
(Figure II-4B). However, the similar LQTS mutation in E2 (T8A) is not predicted 
to cause catastrophic loss of N-glycosylation in healthy cells because the 
remaining N29 consensus site in wild type E2 contains a threonine. Satisfyingly, 
the results with singly glycosylated E2 mutant (N29, T31) are in agreement this 
prediction (Figure II-4B).  
The strong co-translational preference for NXT sites indicates that the loss 
of a single methyl group in the consensus site may not be benign in type I 
transmembrane peptides. Under certain circumstances (i.e. drug-induced, stress, 
etc.), the shift to post-translational N-glycosylation and mild hypoglycosylation 
caused by a threonine to serine mutation (Figures II-2 and II-4) may be sufficient 
to result in a disease state. Consistent with this mild hypoglycosylation/ 
haploinsufficiency hypothesis are the Brugada syndrome (E3: T4A) [124] and 
antibiotic-induced long QT syndrome mutations (E2: T8A, Q9E) [77,123] that 
eliminate or flank consensus sites in other KCNE peptides. For the drug-induced 
mutations that increase hERG K+ channel sensitivity to macrolide antibiotics, the 
additional presence of the drug could perturb the already delicate balance of co- 
and post-translational N-glycosylation of these mutant E2 proteins. Similarly, the 
T4A mutation that immediately precedes the first consensus site in E3 is in a 
position to alter the kinetics of N-glycosylation. Future kinetic studies that 
examine the central and flanking consensus site residues in type I 
transmembrane peptides will further refine the determinants of N-glycan 
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attachment to better predict the disease-causing mutations that effect N-
glycosylation.  
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CHAPTER III: CONSENSUS SITE MIDDLE RESIDUE AFFECTS THE 
DISTRIBUTION OF CO- AND POST-TRANSLATIONAL N-GLYCOSYLATION 
FOR TYPE I TRANSMEMBRANE PEPTIDES 
 
Abstract 
 
Asparagine (N)- linked glycosylation is essential for efficient protein folding 
in the endoplasmic reticulum (ER) and anterograde trafficking along the secretory 
pathway. N-glycans are attached to a nascent polypeptide at a consensus site of 
N-X-T/S-Y (X,Y ≠ P) by one of two enzymatic isoforms of the 
oligosaccharyltransferase (OST), STT3A or STT3B. We show that these two 
isoforms are linked to co- and post-translational N-glycosylation respectively for 
type I transmembrane peptides, in agreement with previous findings for other 
peptide topologies. We also examined the effect of the consensus site X residue 
on the distributions of co- and post-translational N-glycosylation on a type I 
transmembrane scaffold peptide (KCNE2). For NXS sites, large hydrophobic and 
negatively charged residues significantly hinder co-translational N-glycosylation. 
This deficiency in co-translational N-glycosylation can be recovered by 
conversion to an NXT site. The post-translational rates of N-glycosylation were 
also examined and a correlation was found between the amount of co-
translational N-glycosylation and the rate of post-translational N-glycosylation, 
implicating similar enzymatic mechanisms for the OST STT3 isoforms. 
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Introduction 
 
Asparagine (N)-linked glycosylation occurs for the vast majority of 
secretory and membrane bound proteins that require an N-glycan in order to 
ensure efficient trafficking out of the endoplasmic reticulum (ER). The covalent 
attachment of the 14-sugar oligosaccharide to a nascent chain at a consensus 
site of N-X-T/S-Y, where X and Y can be any amino acid except proline, is 
catalyzed by the oligosaccharyltransferase (OST) [14,15]. This ER luminal 
membrane protein complex is composed of seven or eight individual subunits in 
eukaryotes and undergoes a vast array of diverse functions, including positioning 
the lipid-linked oligosaccharide donor and scanning and positioning a peptide 
chain for N-glycosylation. This process can occur co-translationally along side 
the Sec61 complex, which transfers growing peptides across or into the ER 
membrane [8], or post-translationally after the peptide is fully synthesized [8,36]. 
The OST catalytic subunit STT3 is the only domain of the complex that is 
conserved from eukaryotes to eubacteria [17]. For vertebrates, insects, and 
plants, there are two known eukaryotic isoforms of the OST catalytic subunit 
designated STT3A and STT3B, and these have recently been linked to two, 
temporally distinct pathways of N-glycosylation for water-soluble, type II, and 
multi-spanning transmembrane glycoproteins [30,41,42]. Utilizing kinetic assays, 
the OST STT3A isoform has been shown to predominantly perform co-
translational N-glycosylation while the OST STT3B isoform preferentially N-
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glycosylates peptides post-translationally. Intriguingly, STT3B was found to 
perform co-translational N-glycosylation if STT3A is depleted, but STT3A does 
not perform post-translational N-glycosylation in the absence of STT3B [30], 
implicating at least affinity differences between these different OST isoform 
complexes. No structure of either STT3 isoform has been solved; however, 
crystal structures for the OST homologs of bacterial C. lari PglB [25] and 
archaeal A. fulgidus AglB [26] have been determined. Despite having only 20% 
sequence identity, these structures were remarkably similar and were concluded 
to function by a mutually conserved catalytic mechanism. 
Primary sequence context of an N-linked glycosylation consensus site has 
been known to effect the efficiency of N-glycan attachment, including the 
hydroxyl residue in the consensus site [63,64], the middle residue in the 
consensus site [67,68], specific residues upstream or downstream of the 
consensus site [69,71] including the residue immediately following the hydroxyl 
position [66], and the proximity of the consensus site to other consensus sites 
[39] and the C-terminus [42].  Although many factors are known that affect the 
efficiency of N-glycosylation, particularly for NXS consensus sites, a plausible 
mechanism for this disparity has not been determined, nor have the distributions 
of co- and post-translational N-glycosylation efficiencies and the biophysical 
ramifications of these differences in the context of the OST STT3A and STT3B 
isoforms been characterized. 
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Here, we use a type I transmembrane scaffold glycopeptide (KCNE2) to 
determine the co- and post-translational N-glycosylation distributions for all 
amino acids in the middle residue of the consensus site.  We have found that 
bulky hydrophobic residues and negatively charged residues hinder co- and post-
translational N-glycosylation, while small hydrophobics, positively-charged, and 
polar residues are efficiently N-glycosylated through co-translational N-
glycosylation. We determine the post-translational rates of N-glycosylation for X 
residues in NXS sites and report a correlation between the post-rate and the 
amount of co-translational N-glycosylation. Finally, we identify the enzymatic 
isoforms associated with N-glycosylation mechanisms for NXS and NXT type I 
transmembrane glycopeptide consensus sites: STT3A predominantly performs 
co-translational N-glycosylation and STT3B predominantly performs post-
translational N-glycosylation. This is in agreement with previously determined 
roles for these OST subunits on water-soluble and type II transmembrane 
proteins [30,42]. Our finding that a correlation exists for co- and post-translational 
N-glycosylation of NXS sites provides evidence that STT3A and STT3B 
glycosylate at similar efficiencies, and implies that these isoforms likely function 
by a conserved catalytic mechanism. 
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Materials and Methods 
 
Cloning and plasmids:  Human KCNE2 and KCNE4 were cloned into 
pcDNA™3.1(-) vector such that five additional methionine residues and an HA tag 
(YPYDVPDYA) were added to the C-terminus of each KCNE peptide [2,40]. The 
second N-glycosylation consensus site was removed in KCNE2 by mutation to 
glutamine (N29Q). Mutations for creating different X residues in NXS or NXT 
sites were introduced using traditional PCR cassette mutagenesis (Syzygy 
Biotech Taq 2x MeanGreen Master Mix) between the 5’ KpnI and 3’ BglII sites. 
All constructs were confirmed by DNA sequencing the entire gene.  
 
Cell culture and plasmid transfection for western blot: Chinese hamster 
ovary-K1 (CHO) cells were maintained in Gibco-F12K Nutrient Mixture, Kaighn’s 
Modification (with L-glutamine) media, supplemented with 10% FBS (Sigma) and 
1% penicillin/streptomycin. Cells were passaged using 0.5% Trypsin-EDTA and 
plated onto 35 mm dishes at 80% confluency.  After 24 h, the cells were 
transiently transfected with a mixture of 1.5 µg KCNE DNA and 8 µL 
Lipofectamine in 1 mL OptiMem.  After 6 h at 37°C, the transfection cocktail was 
removed and 2 mL of F12K media with supplements was added and the cells 
were incubated for 40-45 h. 
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Plasmid transfection for pulse-chase: Cells were passaged using 0.5% 
Trypsin-EDTA and plated onto 100 mm dishes at 80% confluency.  After 24 h, 
the cells were transiently transfected with a mixture of 3 µg KCNE DNA and 80 
µL Lipofectamine in 2 mL OptiMem.  After 6 h at 37°C, the transfection cocktail 
was removed and 10 mL of F12K media with supplements was added and the 
cells were incubated for 15-20 h. 
 
siRNA transfection for pulse-chase and western blot: Cells were passaged 
using 0.5% Trypsin-EDTA and plated onto 100 mm dishes at 80% confluency.  
After 24 h, the cells were transiently transfected with a mixture of small interfering 
RNA (siRNA):  
(scr. A+B): 100 nmol scrambled A (GAGAACUAACGCAAGAGAAdTdT) +  
150 nmol scrambled B (GAAGGCACCGGUUAUUAGUdTdT);  
(A): 100 nmol A (GAAGACACAUCAAGGAGAAdTdT);  
(B): 150 nmol B (GGACUACUCUGGUGGAUAAdTdT); or 
(A+B): 100 nmol A + 150 nmol B.  
Incubated 5 min individually before combining with 80 µL Lipofectamine 2000 in 
OptiMem for 30 min, then diluted into 2 mL OptiMem.  After 6 h at 37°C, the 
transfection cocktail was removed and 2 mL of F12K media with supplements 
was added and the cells were incubated for 40-45 h. Another round of siRNA 
transfection was then performed as above, this time adding 3 µg E2 scaffold 
DNA along with the siRNAs. After another 6 h at 37°C, the transfection cocktail 
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was removed and 2 mL of F12K media with supplements was added and the 
cells were again incubated for 40-45 h. 
 
Pulse-chase assays and cell lysis:  Pulse-chase experiments and cell lysis 
were performed as previously described [40]. Briefly, transfected cells were 
washed with PBS and incubated for 35 min at 37°C in Gibco DMEM High 
Glucose Media (4.5 g/L D-glucose, lacking L-methionine and L-cysteine), 
supplemented with 10% FBS, 1% Pen Strep, and 2 mM L-glutamine.  The media 
was removed and the cells were incubated at 37°C for 2 min in DMEM High 
Glucose Media containing 100µCi/mL EasyTag EXPRESS [35S] Protein Labeling 
Mix (Perkin Elmer). The radioactive media was removed and the cells were 
washed with PBS and chased with F12K media for 3, 6, 9, or 12 min at 37°C.  
The cells were then washed with PBS and lysed with 750 µL of low salt lysis 
buffer (in mM): 50 TRIS-HCl, pH 7.4, 150 NaCl, 20 NaF, 10 Na3VO4, 1% NP-40, 
1% CHAPS, which was supplemented with protease inhibitors: 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1µg/mL each of leupeptin, pepstatin, 
and aprotinin (LPA).  Cells were lysed for 30 min with vigorous shaking a 4°C, 
and the cell debris scraped and pelleted at 14,000 rpm for 10 min at room 
temperature. 
 
Radioimmunoprecipitation and electrophoresis for pulse-chase: 
Radioimmunoprecipitation and electrophoresis for pulse-chase were performed 
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as previously described [40]. Briefly, Protein G agarose beads (Pierce) were 
prepared by washing in low salt lysis buffer.  After pelleting the cell debris, the 
supernatant was precleared with 50 µL beads for 2 hours at 4°C.  The beads 
were then spun down, and the supernatant transferred to new tubes containing 
25 µL beads pre-incubated with 1 µL monoclonal anti-HA antibody (Sigma). After 
an overnight incubation at 4°C, the beads were pelleted, the supernatant 
removed and the beads were subjected to 3 washes of low salt lysis buffer, 1 
wash of high salt buffer: 50 mM TRIS-HCl, pH 7.4, 500 mM NaCl, 1% NP-40, 1% 
CHAPS, 20 mM NaF, 10 mM Na3VO4, and a final wash with low salt lysis buffer. 
For enzymatic deglycosylation assays, 1 µL Endo Hf (New England Biolabs) was 
added to beads in 50 µL low salt lysis buffer and incubated at 37°C for 1 hour.  
Peptides were eluted from the beads with 100 mM DTT and 2x SDS gel loading 
buffer at 55°C for 15 min.  Samples were analyzed by 15% SDS-PAGE and the 
gels were dehydrated for 1 h in a 30% ethanol, 2% glycerol solution.  Gels were 
dried for 2 h at 80°C, applied to film, and analyzed for autoradiography by 
Typhoon FLA-9000 phosphoimager after 14 – 42 d. 
 
Cell lysis and electrophoresis for western blots: Cells were washed in PBS (3 
x 750 µL) and treated with RIPA cell lysis buffer: 10 mM TRIS-HCl, pH 7.4, 140 
mM NaCl, 1 mM EDTA pH 7.4, 1% Triton X-100, 0.1% SDS, 1% sodium 
deoxycholate, supplemented with protease inhibitors (PMSF and LPA, see pulse 
chase). Cells were lysed for 30 min with vigorous shaking at 4°C, and the cell 
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debris scraped and pelleted at 14,000 rpm for 10 min at room temperature. Total 
protein in each sample was determined by bicinchonimic acid (BCA) assay and 
60 µg protein utilized for electrophoresis. Samples were prepared by adding 100 
mM DTT and 2x SDS gel loading buffer to the lysis sample to a total volume of 
50 µL. Samples were analyzed by 8% SDS-PAGE, transferred to nitrocellulose 
membrane, and blocked for 30 min in milk (5% nonfat dry milk in Tris-buffered 
saline containing 0.2% Tween-20 (Western wash buffer)). Primary antibody 
(STT3A 1:2,500 or STT3B 1:6,000) was obtained from R. Glimore’s lab [30]. The 
primary antibody was added overnight by diluting into Western blocking buffer. 
Membranes were then washed in Western wash buffer (3 x 6 mL) for 5 min each, 
and secondary antibody (STT3A 1:4,000 or STT3B 1:10,000 [30] was added in 
Western blocking buffer for 45 min at room temperature. More washes were 
performed (3 x 6 mL western wash buffer) and the membrane was incubated with 
SuperSignal West Dura Extended Duration Substrate (Pierce) for 5 min and the 
chemiluminescence captured using a LAS-3000 CCD camera and quantified by 
Multi Gauge software (Fujifilm). 
 
Determination of co- and post-translational N-glycosylation: All signals were 
quantified using Image Gauge software (Fujifilm) [40]. For all constructs, 
percentage of glycosylation was determined by dividing the signal of the 
glycosylated species by the total amount of signal (0-Gly + 1-Gly) per time point. 
Percent total N-glycosylation is the amount present at the end of the time course 
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(12 min) and the error in total N-glycosylation graphs is that associated with this 
time point. To determine the co-translational N-glycosylation contribution for each 
construct, we divided the percent N-glycosylated at 0 min by the percent N-
glycosylated at 12 min. Our simplified calculation for co-translational N-
glycosylation assumes that the peptide substrates are fully synthesized before 
the 3 min time point [72] and that the observable rates for co- and post- 
translational N-glycosylation are substantially different for this class of peptides 
[2]. For the post-translational N-glycosylation contribution, we subtracted out the 
0 min contribution (12 - 0 min percent N-glycosylation) and divided this by the 
total N-glycosylation (12 min). For percent total N-glycosylation graphs, co- (solid 
bars) and post- (slashed bars) contributions are shown, with the errors between 
this interface shown for both co- (up error) and post- (down error). Post-
translational N-glycosylation kinetic rates (k) were determined by fitting the data 
to a one-phase association equation: Y = Y0 + (Plateau-Y0)(1-e(-kx)). 
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Results 
 
In order to determine the consensus site X residue effects on co- and 
post-translational N-glycosylation for type I transmembrane peptides, we first 
needed to identify an ideal, kinetically sensitive peptide candidate that would 
allow for the highest resolution of N-glycan attachment mechanistic shifts. We 
previously determined that the N-glycosylation kinetics of the KCNE family (E1-
E5) are sensitive to primary sequence changes and the resulting shifts in co- and 
post-translational N-glycosylation readily detected by metabolic pulse-chase [40]. 
We chose E2 and E4 as the most probable candidates for determining middle 
residue effects as their N-glycosylation kinetics are well understood and have 
robust radiolabel incorporation for amplified detection of glycoforms. wtE2 has 
two N-glycosylation consensus sites, NFT and NTT, and wtE4 has one 
consensus site, NST. Since it is known that NXS consensus sites have higher 
sensitivity to the X residue for N-glycosylation efficiency [67], we decided to first 
look at X residues in the presence of NXS sites for E2 and E4. The second N-
glycosylation consensus site in E2 was removed by asparagine mutation to 
glutamine for simplified tracking of the N-glycosylation kinetics of this peptide. 
Based on previous consensus site X residue efficiency rankings [67], we 
first chose to observe the N-glycosylation kinetics of E2 and E4 peptides using 
three ranging residues: NSS, NFS, and NWS (Figure III-1A). The unglycosylated 
(0-Gly) and singly glycosylated (1-Gly) species were readily observable to 
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Figure III-1. E2 and E4 N-glycosylation kinetics of NXS sites alter co- and 
post-translational distributions. (A) Cells were pulsed for 2 min and chased for 
indicated times. Immunoprecipitated E2 (one NXS site at N6) and E4 (one NXS 
site at N8) proteins were separated by electrophoresis and detected by 
autoradiography. Glycosylated (1-Gly) and unglycosylated (0-Gly) species are 
labeled for NSS, NFS, and NWS consensus sites. 1-Gly species not detected for 
E4 NWS. (B) EndoH treatment for E2 and E4 NXS consensus sites. All 
experiments were performed at the same time. Glycosylation species are 
labeled. (C) Left graph: Plots of maximally glycosylated (1-Gly) species for NSS 
sites in E2 (black triangles) and E4 (gray triangles). Co- and post-translational N-
glycosylation divisions are shown. Right graph: Quantification for maximally 
glycosylated (1-Gly) species for all E2 and E4 sites: E2 (black), E4 (gray): NSS 
(triangles), NFS (squares), NWS (circles). (D) Co-, post-, and total N-
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glycosylation for E2 (black) and E4 (gray) consensus sites. Total N-glycosylation 
divisions show co- (solid) and post- (slashed) translational contributions with 
errors for co- (middle bar, up), post- (middle bar, down), and total (top bar, up) N-
glycosylation. Error bars are ± s.e. from 3 experiments. n.d., not detected. 
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varying intensities for all consensus sites except for E4 NWS where no 1-Gly 
species was observable. The 0-Gly species was confirmed by endoglycosidase 
H digestion for peptides where both species were not readily detected (Figure III-
1B). We first quantified our signal as was previously reported [40]; for each 
peptide and construct, the 1-Gly intensity was normalized to the total 
glycosylation for each time point, and the resulting percentage of maximal 
glycosylation graphed (Figure III-1C).  The co- and post- contributions can be 
determined from the total glycosylation by exploiting the temporal distinctions 
between these two mechanisms. Because post-translational N-glycosylation is 
significantly slower than co-translational N-glycosylation [30], a simplified 
convention can be utilized where the co-translational contribution is defined as 
what is present at the beginning of the chase period (0 min) and the post-
translational contribution is defined as the increase in glycosylation seen over the 
time course (12 min – 0 min; Figure III-1C left). Because these X residue 
consensus site kinetic differences can be slight and difficult to observe directly on 
a linear plot (Figure III-1C right), we chose to individually graph the co-
translational, post-translational, and total N-glycosylation for each peptide’s 
consensus site (Figure III-1D). Now it is readily observable that while E2 and E4 
both show varying N-glycosylation kinetic rates from varying consensus site X 
residues, E2 appears to be more sensitive to these changes, ranging from about 
90% to 20% N-glycosylation between S and W in total N-glycosylation (Table III-
1). 
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 % Co- % Post- % Total 
 E4 NXS 
W n.d. n.d. n.d. 
F 24.1 ± 3.9 20.3 ± 4.2 44.4 ± 1.3 
S 22.0 ± 1.9 22.1 ± 2.3 44.2 ± 1.3 
 E2 NXS* 
W 17.2 ± 3.9 n.d. 17.2 ± 3.9 
L 15.4 ± 1.6 8.5 ± 2.1 23.8 ± 1.4 
F 31.0 ± 3.1 28.0 ± 3.3 59.0 ± 1.2 
I 38.2 ± 3.1 23.1 ± 3.4 61.3 ± 1.2 
E 40.2 ± 4.2 23.2 ± 4.9 63.4 ± 2.6 
M 46.2 ± 0.4 26.2 ± 0.7 72.4 ± 0.6 
D 63.6 ± 3.0 19.0 ± 3.5 82.6 ± 1.8 
K 60.5 ± 3.7 23.2 ± 4.8 83.8 ± 3.1 
Y 60.4 ± 2.3 25.8 ± 2.8 86.6 ± 2.7 
G 71.1 ± 1.7 16.8 ± 2.6 87.9 ± 1.9 
N 74.3 ± 0.9 14.2 ± 4.4 88.5 ± 4.3 
V 64.1 ± 1.0 24.9 ± 1.0 89.0 ± 0.1 
C 84.8 ± 6.7 4.5 ± 7.4 89.3 ± 3.1 
Q 74.6 ± 5.1 16.2 ± 5.2 90.7 ± 1.1 
R 67.3 ± 6.2 23.5 ± 6.3 90.8 ± 1.2 
H 81.3 ± 6.6 10.3 ± 8.0 91.6 ± 4.5 
S 76.9 ± 3.9 15.4 ± 4.0 92.3 ± 0.9 
T 72.2 ± 3.9 20.6 ± 4.4 92.8 ± 2.0 
A 72.9 ± 2.4 20.1 ± 2.6 92.9 ± 1.0 
 E2 NXT 
W 41.9 ± 1.8* 30.5 ± 2.6* 72.4 ± 1.9* 
L 68.3 ± 0.7* 17.9 ± 2.3 86.2 ± 2.2* 
E 70.8 ± 0.7* 17.3 ± 5.7 88.1 ± 5.6* 
F 74.4 ± 2.8* 18.0 ± 3.7 92.5 ± 2.5* 
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 E2 NFT (OST STT3 knockdown) 
scr. A+B 63.8 ± 2.0 24.0 ± 4.1 87.8 ± 3.6 
A 63.8 ± 2.3 24.3 ± 3.4 88.1 ± 2.5 
B 51.1 ± 3.7* 14.6 ± 4.0* 65.7 ± 1.5* 
A+B 22.0 ± 5.0* n.d. 22.0 ± 5.0* 
 E2 NFS (OST STT3 knockdown) 
scr. A+B 35.5 ± 1.7 18.2 ± 2.0 53.7 ± 1.0 
A 31.7 ± 1.2 20.9 ± 1.6 52.7 ± 1.1 
B 40.2 ± 0.6 n.d. 40.2 ± 0.6* 
A+B 14.9 ± 1.3* n.d. 14.9 ± 1.3* 
 
 
Table III-1. Consensus site middle residue N-glycosylation. Co-translational, 
post-translational, and total N-glycosylation shown for each E2 or E4 NXS or 
NXT middle residue consensus site. The percentages of co- and post-
translational N-glycosylation were determined as described in the methods 
section. Values are mean ± s.e.m. for 3 pulse-chase experiments. n.d., not 
determined. *, p < 0.05 (one-way ANOVA for NXS sites, two-way ANOVA for 
NXS vs. NXT sites) * next to values indicates significance by Tukey’s multiple 
comparison test (E2 NXT values compared to equivalent E2 NXS sites; siRNA 
knockdown values compared against scr. A+B control). 
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We next determined the N-glycosylation kinetics for all consensus site 
middle amino acids (except proline) using E2 as a scaffold type I transmembrane 
peptide (Figure III-2A). The co-translational, post-translational, and total N-
glycosylation quantifications are shown in Figure III-2B. The co-translational N-
glycosylation of consensus sites is most affected by large hydrophobic (left 
graph, green bars) and negatively charged residues (coral bars). Polar and small 
hydrophobics (purple bars) as well as positively charged residues (navy bars) are 
efficiently co-translationally N-glycosylated NXS sites. In agreement with the 
temporal divisions between co- and post-translational N-glycosylation, the largest 
post-translational contributors are the less efficiently co-translationally N-
glycosylated NXS sites (Figure III-2B, middle graph). The availability of a larger 
pool of unglycosylated substrates most likely enhances this contribution for post-
translational N-glycosylation. However, this slight increase is not enough to 
compensate for the poor co-translational contributions for the large hydrophobic 
middle residues, keeping the total N-glycosylation efficiency for these consensus 
sites significantly below the other sites (Figure III-2B, right graph).  
We next wanted to see if our poorest N-glycosylation NXS sites could be 
recovered to higher N-glycosylation efficiencies by mutation to NXT sites as has 
been previously observed [40,42], and determine which N-glycosylation 
contributions would be greatest effected for each middle residue assayed. We 
observed the N-glycosylation kinetics for NWT, NLT, NET, and NFT and found 
that all consensus sites were significantly improved (Figure III-2C). NWT and 
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Figure III-2. N-glycosylation of an E2 NXS site is most hindered by large 
hydrophobic and negatively charged residues at the X position. (A) 
Representative fluorographs from pulse-chase experiments for X residues in an 
E2 NXS consensus site. Glycosylated (1-Gly) and unglycosylated (0-Gly) species 
are labeled. Side: E2 NCS glycospecies confirmation by EndoH. (B) Graphs for 
co-, post-, and total N-glycosylation contributions for the consensus site X 
residues. Coloring by the biophysical properties of each residue: polar and small 
hydrophobics (purple), positively charged (navy), negatively charged (coral), 
large hydrophobics (green). Total N-glycosylation divisions show co- (solid) and 
post- (slashed) translational contributions with errors for co- (middle bar, up), 
post- (middle bar, down), and total (top bar, up) N-glycosylation. (C) Left: 
Representative fluorographs from pulse-chase experiments for several NXT 
sites. Glycosylated (1-Gly) and unglycosylated (0-Gly) species are labeled. Right: 
Graph showing total N-glycosylation with co- (solid bars) and post- (slashed bars) 
translational N-glycosylation divisions for NXS (black) and NXT (purple) sites with 
common X residues. Errors are shown for co- (middle bar, up), post- (middle bar, 
down), and total (top bar, up) N-glycosylation. Error bars are ± s.e. from 3 
experiments. n.d., not detected. 
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NLT were more efficient for both co- and post-translational N-glycosylation than 
their NXS counter parts. NET and NFT saw improvement in only co-translational 
N-glycosylation, again implicating the temporal divide of post-translational N-
glycosylation with a finite pool of peptide substrates and indicating that the 
highest level of N-glycan occupancy has been reached for these sites. 
We next wanted to quantify the kinetic rates for post-translational N-
glycosylation of the middle X residue consensus sites to see how these findings 
compared to the measured co-translational N-glycosylation. While a precise, 
physiological rate of N-glycosylation from our pulse-chase assay can not be 
determined due to an inability to control substrate, enzyme, and competitor 
concentrations as well as the rate of protein degradation in living cells, we can 
compare our observed N-glycosylation kinetic rates for each middle X residue as 
a controlled approximation. We first scaled our pulse-chase kinetics to zero to 
remove the co-translational N-glycosylation contribution and fit the data to a one-
phase association equation (Figure III-3A). We observed a significant difference 
among post-translational N-glycosylation rates for different middle residues, 
where once again large hydrophobic residues had the slowest rates of N-
glycosylation (Figure III-3B, upper graph and Table III-2). We next compared the 
post-translational N-glycosylation kinetic rate of each middle X residue to its 
measured amount of co-translational N-glycosylation (Figure III-3B, lower graph), 
and found a significant correlation (R2 = 0.76). This is the first evidence by 
detection of N-glycan attachment that co- and post-translational N-glycosylation 
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Figure III-3. Post-translational N-glycosylation rates reveal a similar 
efficiency towards consensus site X residues as co-translational N-
glycosylation. (A) Kinetics of post-translational N-glycosylation for each X 
residue with measurable post- contributions. Scaled to zero for direct 
comparison. (B) Post-translational N-glycosylation rates for consensus site X 
residues. Coloring by the biophysical properties of each residue: polar and small 
hydrophobics (purple), positively charged (navy), negatively charged (coral), 
large hydrophobics (green). One-way ANOVA performed showing p < 0.05. (C) 
Correlation of co- and post-translational N-glycosylation efficiencies for varying X 
residues. Coloring is the same as in (B). R2 = 0.76, p < 0.05. Error bars are ± s.e. 
from 3 experiments. n.d., not detected. 
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 Post-rate (min-1)* 
S 0.284 ± 0.050 
R 0.253 ± 0.022 
N 0.247 ± 0.066 
H 0.226 ± 0.053 
C 0.221 ± 0.112 
Y 0.205 ± 0.073 
G 0.194 ± 0.062 
Q 0.189 ± 0.033 
V 0.187 ± 0.015 
E 0.183 ± 0.036 
D 0.176 ± 0.077 
T 0.194 ± .043 
A 0.146 ± 0.048 
K 0.123 ± 0.020 
M 0.116 ± 0.019 
F 0.096 ± 0.028 
I 0.055 ± 0.020 
L 0.002 ± 0.002 
W n.d. 
 
 
Table III-2. NXS middle residue post-translational N-glycosylation rates. 
Post-translational N-glycosylation rates for all X residues in the E2 NXS 
consensus site. Rates were averaged from independent pulse-chase 
experiments where the association rate (k) was determined by fitting the data to 
a one-phase association equation: Y = Y0 + (Plateau-Y0)(1-e(-kx)). Values are 
mean ± s.e.m. for 3 experiments, except for NKS which is 2 experiments. n.d., 
not detected. *, p < 0.05 (one-way ANOVA). 
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work at similar efficiencies, and therefore the OST STT3 isoforms associated 
with each pathway most likely work by a similarly conserved mechanism. 
To definitively link the two N-glycosylation pathways to specific STT3 
enzymatic isoforms for type I transmembrane peptides, we adapted an STT3 
small interfering RNA (siRNA) knockdown approach [30,42] for CHO cells as 
described in the Methods section. Using two siRNA transfections, we were able 
to knockdown STT3A 73.8 ± 3.3% alone and 57.3 ± 4.3% in combination with 
STT3B. STT3B was knocked down 62.8 ± 6.0% alone or 69.7 ± 2.3% in 
combination with STT3A. Scrambled sequences or siRNA for the opposite 
isoform had no significant effect on STT3 protein levels (Figure III-4).   
For these experiments we chose the native E2 phenylalanine middle 
residue as our N-glycosylation substrate. Pulse-chases were performed with 
transfection of NFT or NFS DNA along with an siRNA treatment of scrambled 
A+B, A, B, or A+B (Figure III-5A). For the NFS site, we saw a significant 
reduction of co-translational N-glycosylation when treated with A+B siRNA 
(Figure III-5B). Our observation that knocking down STT3A alone does not affect 
co-translational N-glycosylation is in agreement with previous findings that 
STT3B can fulfill a co-translational role when STT3A is not present [30].  We are 
confident that this is occurring because while knocking down STT3B alone had 
no effect on co-translational N-glycosylation, adding STT3A with STT3B 
produces significant reduction (Figure III-5B, NFS co-contribution double 
knockdown). Post-translational N-glycosylation is significantly reduced for STT3B 
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Figure III-4. OST STT3A and STT3B isoforms are specifically and efficiently 
knocked down upon siRNA treatment. Representative western blots for 
STT3A (top) and STT3B (bottom). Graphs for each are shown directly below 
each image, each knockdown is normalized to the scrambled A+B treatment. 
Error bars are ± s.e. from 3 experiments. M.M., microsomal membranes. Scr. A, 
Scr. B, A, and B lanes depict treatment with that siRNA. , non-specific band. *, p 
< 0.05.  
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Figure III-5. OST catalytic isoforms STT3A and STT3B perform co- and 
post-translational N-glycosylation, respectively, for type I transmembrane 
peptides in NXS and NXT sites. (A) Representative fluorographs from pulse-
chased siRNA treated CHO cells expressing either E2 NFS or E2 NFT. The 
specificity of each siRNA is shown on the left. Glycosylated (1-Gly) and 
unglycosylated (0-Gly) species are labeled. (B) Graphs for co- (top), post- 
(middle), and total (bottom) N-glycosylation contributions for NFS (black) and 
NFT (gray) consensus sites. Total N-glycosylation divisions show co- (solid) and 
post- (slashed) translational contributions with errors for co- (middle bar, up), 
post- (middle bar, down), and total (top bar, up) N-glycosylation. (C) Post-
translational N-glycosylation rates shown for E2 NFT and NFS sites under 
scrambled double knockdown conditions. The fits are extrapolated back to -2 
minutes. Vertical dashed line marks 0 minute. Horizontal dashed line marks y-
intercept. The percentage on each graph is the difference between the 0 minute 
and -2 minute intercepts. Error bars are ± s.e. from 3 experiments. n.d., not 
detected. *, p < 0.05. 
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and double knockdowns to the extent that these are no longer detectable. This 
also is in agreement with the previous finding that STT3A does not compensate 
for post-translational N-glycosylation when STT3B levels are reduced [30]. 
STT3 knockdown for the NFT site proceeded similarly; co-translational N-
glycosylation for STT3A knockdown alone showed no effect, but a significant 
reduction was seen for the double knockdown, and post-translational N-
glycosylation was reduced for both knockdown of STT3B alone and in 
combination with STT3A. Surprisingly, we did see a slightly significant reduction 
in co-translational N-glycosylation upon knockdown of STT3B alone for the NFT 
site. Because this reduction is only present in the NFT site, we believe that this 
disparity arises from high efficiency of NXT sites and the limitations of our co- 
and post-translational N-glycosylation kinetic definitions. Figure III-5C shows the 
post-translational N-glycosylation kinetics for NFT and NFS peptides under the 
control knockdown (scr. A+B). When these fits are extrapolated back to -2 min, 
the beginning of the pulse, it is evident that the NFT site is twice as likely to 
contain post-translational events during this 2 min pulse period due to its higher 
kinetic rate. This indicates that some highly efficient N-glycosylation consensus 
sites might be slightly misrepresented in our co- and post- definitions and will be 
addressed in the discussion.  
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Discussion 
 
We have identified the contributions of co- and post-translational N-
glycosylation for NXS sites by systematically screening the middle residue in an 
E2 scaffold peptide. We found that large hydrophobic middle residues and 
negatively charged residues receive the least co-translational N-glycosylation. 
While these residues have a slightly higher rate of post-translational N-
glycosylation, it is not sufficient to recapitulate the total N-glycosylation of more 
efficient N-glycosylation sites containing polar and positively charged residues.  
We also examined the rates of post-translational N-glycosylation and 
found that when we compared these rates to the percent of co-translational N-
glycosylation contribution there was a significant correlation between efficiencies 
of co-amount and post-rate implicating similar mechanisms for the OST isoforms. 
This implies that the amount of time a peptide spends adjacent to the OST is a 
key factor in consensus site recognition, especially for co-translational N-
glycosylation where the peptide only remains in the associated translocon until 
translation is complete [8]. Thus, the kinetic differences we observe between co- 
and post-translational N-glycosylation are purely spatiotemporal in nature and not 
dependent on the mechanism of N-glycosylation. 
We then identified the OST STT3 isoforms behind co- and post-
translational N-glycosylation for NXS and NXT consensus sites, and found that 
STT3A predominantly performs co-translational N-glycosylation while STT3B 
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predominantly performs post-translational N-glycosylation, in agreement with the 
roles of these isoforms on other topological proteins [30,42]. While the NFS 
consensus site displayed high sensitivity to disruption of either OST STT3 
isoform, STT3B knockdown of the NFT consensus site reduced co-translational 
N-glycosylation and did not completely inhibit post-translational N-glycosylation. 
This implicates our co- and post-translational N-glycosylation definitions are 
slightly misrepresented for highly efficient consensus sites.  
While a 2 min pulse period is necessary to obtain enough metabolically 
labeled peptide, most likely there are a number of peptides that complete 
translation and exit the translocon during this period. Hemagglutinin, which is 
more than twice the size of the KCNEs, only takes ~ 1 min for detectable 
radiolabel incorporation in a CHO cell pulse-chase assay [72]. Using this as a 
standard, we would then expect KCNE peptides with highly efficient N-
glycosylation sites, like NXT sites, to obtain some post-translational N-glycans 
during the pulse period. The post-translational N-glycosylation kinetics for NFT 
and NFS peptides extrapolated back to -2 min show that the NFT site is twice as 
likely to contain post-translational events during this 2 min window (Figure III-5C). 
This also explains why we don’t see a similar decrease in % co- for the NFS site 
upon STT3B knockdown (Figure III-5B, NFS B knockdown top graph). Therefore, 
a reduction of STT3B for NFT sites could be detected as a slight lost of co-
translational as well as the expected reduction in post-translational N-
glycosylation (Figure III-5B, NFT B knockdowns). Some post-translational N-
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glycosylation would be expected in a B knockdown from the ~35% STT3B 
remaining in these knockdowns and the higher rate of N-glycosylation for these 
efficient NFT consensus sites. 
Co-translational N-glycosylation is less likely to be present in our post- 
definition because of the rapid (< 1 min) depletion of metabolic radiolabel that 
has been observed during chase times using proteins with evenly distributed 
methionines [72]. The KCNEs are heavily back loaded with 5 extra methionines 
engineered onto the C-terminus for enhanced signal, which would further 
increase the rate of radiolabel depletion. Therefore, we would expect to observe 
only post-translation N-glycosylation in our co- definition for highly efficient N-
glycosylation consensus sites. This would be represented in our data by slightly 
higher than expected co-translational N-glycosylation and lower than expected 
post-translational rates, which is exactly what is seen in the % co- and post-rate 
correlation plot of NXS sites (Figure III-3B lower graph). The highly efficient polar 
X residues are clustered slightly above and to the left of the fit. This finding also 
holds true for other KCNE consensus sites (Figure III-6). For an E1, E2, E4, and 
E5 single consensus site comparison, the more efficiently N-glycosylated 
consensus sites (all E5 sites, and E2 and E4 NXT sites) clustered slightly higher 
and to the left of an expected linear trend. Overall, these findings, while important 
for precise comparisons, do not affect the general determinants of co- and post-
translational N-glycosylation for any KCNE consensus sites studied to date. 
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Figure III-6. A correlation between KCNE co-translational and post-
translational N-glycosylation from several consensus sites shows co- and 
post- definition accuracy. Plot of % co- and post-translational rate for several 
KCNE consensus sites. N-glycosylation rates are from previously published 
findings [2,41]. All peptides are single consensus site KCNE constructs for a 
similar rate comparison. Number in each data point reflects the consensus site 
position (1st or 2nd) in that peptide. Black data points are the E2 NXS consensus 
site data shown in Figure III-3. R2 = 0.67, p < 0.05. Error bars are ± s.e. from 3 
experiments. 
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When we previously characterized the N-glycosylation kinetics of KCNE5 
(E5), which contains two NXS sites, it was discovered that both sites were 
efficiently N-glycosylated despite a strong hydroxyl preference in the rest of the 
family [40]. Upon further examination, we now see that this likely is due to the 
role of the middle residue in these sites, which are cysteine and alanine, both 
efficiently N-glycosylated NXS consensus sites. This implies that unlike the other 
wtKCNEs that mostly contain NXT sites, E5 likely evolved an efficient middle 
residue over a more efficient hydroxyl residue, and implicates multiple avenues 
of evolution to ensure high N-glycan occupancy rate. In evidence, a recent 
computational study by R. Gilmore showed that amongst mouse glycoprotein 
NXS consensus sites determined to be occupied in vivo [129], cysteine in 
particular is overrepresented (unpublished data by personal communication). 
While most of the observable rates of N-glycosylation for the KCNEs have 
been explained by the determinants identified to date (hydroxyl preference, 
number of consensus sites, length of the C-terminus, and type of middle residue) 
[2,40], several standing questions from the KCNE family remain. For instance, 
the second consensus site in E2 is not glycosylated as an NTS site when 
expressed alone, despite the efficient threonine middle residue. This hints at 
remaining determinants still to be characterized that effect N-glycosylation for 
type I transmembrane peptides. Further, defining how the dependency of these 
determinants on peptide length and peptides of other topologies would affect the 
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distribution of co- and post-translational N-glycosylation will be necessary for a 
broader understanding of N-glycan site occupancy. 
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CHAPTER IV: DISCUSSION AND FUTURE DIRECTIONS 
 
High N-glycosylation consensus site occupancy is essential for efficient 
trafficking along the secretory pathway. Genetic mutations in any of the many 
proteins and enzymes that regulate this pathway can lead to catastrophic 
consequences and often present as diseases that classify under CDGs [52]. 
What is less clear is how a hypoglycosylated peptide substrate with an intact 
secretory pathway can also lead to disease, like the E1 T7I mutation leading to 
LQTS [122], especially when there are two opportunities for N-glycosylation to 
occur – i.e., co- and post-translational N-glycosylation – and there is evidence 
that some glycopeptides do not need to be N-glycosylated for ER exit and 
forward trafficking and some peptides that traffic through the secretory pathway 
do not contain N-glycosylation consensus sites [60]. 
Here, we approached these questions by identifying determinants in the 
KCNE type I transmembrane peptide family that altered the kinetics of N-glycan 
attachment. In Chapter II, we showed that threonine residues in the consensus 
site and coupled consensus sites are more efficiently co-translationally N-
glycosylated and by the end of our time course have a higher rate of N-glycan 
site occupancy. We also showed that short C-termini hinder co-translational N-
glycosylation, and as a result these glycopeptides have low N-glycan site 
occupancy. In Chapter III, we further characterized determinants by observing 
the N-glycosylation kinetics of the middle X residue in a consensus site and 
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found that large hydrophobic and negatively charged residues hinder both co- 
and post-translational N-glycosylation, resulting in lower N-glycan site 
occupancy. 
 
Structural modeling of X residue consensus sites 
While these findings will be helpful for defining N-glycan occupancy of a 
peptide simply through primary sequence analysis, several questions still remain 
to be answered. Although large hydrophobic X residues hinder co- and post-
translational N-glycosylation kinetics, there is currently no structural explanation 
why these consensus sites hinder N-glycan attachment. To provide a plausible 
mechanism for OST STT3 N-glycosylation variation of diverse consensus sites, 
molecular modeling can be performed simulating different peptide consensus 
sites in the crystal structure of bacterial C. lari PglB [25]. Since the peptide 
crystalized in the recognition site of PglB contains a large angle bend centered 
around the middle residue of the consensus site (Figure I-4), we expect varying 
this residue would effect the time needed for equilibrium of the peptide into the 
recognition site. From our findings in Chapter III, we would predict that bulky 
hydrophobic residues may need significantly more time to equilibrate than small 
polar residues. We would also expect these findings to be applicable beyond 
PglB. While STT3A and STT3B share just 60% sequence similarity with each 
other and only 16% with PglB, the crystal structures for bacterial C. lari PglB and 
aracheal A. fulgidus AglB, despite 20% sequence homology, were found to be 
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remarkably similar [26]. This indicates that structural modeling in PglB would 
most likely be relevant for other OST homologs as well. 
 
Identifying remaining molecular determinants 
While working on characterizing the N-glycosylation kinetics of the first E5 
and E1 consensus sites, we thought that perhaps the distance from the N-
terminus might be aiding in the strong co-translational N-glycosylation of these 
peptides because they are at the second and fifth residues of the peptide 
respectively. We started by making an insertion mutation in E1 (adding ASA 
residues immediately following the methionine) and an E1 chimeric construct with 
E2 (residues leading up to the first site in E1 are the E2 sequence) (Figure IV-
1A). We used E1 constructs that only contained the first consensus site for 
simplicity, and used an NTS site (as opposed to the native NTT site) for added N-
glycosylation kinetic sensitivity. While the E1 add ASA construct has similar N-
glycosylation kinetics to both the wild type N-terminal NTT or NTS sites, 
surprisingly there was a significant decrease in co-translational N-glycosylation in 
the E2/E1 chimera. 
In a reciprocal experiment, in which the equivalent N-terminal sequence in 
E2 was swapped for that of E1 (E2 del S2, Figure IV-1B), there was also a 
significant shift in the N-glycosylation kinetics through an improvement in co-
translational N-glycosylation. These findings indicate that either the length or 
primary sequence of the proximal N-terminus also influences N-glycosylation 
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Figure IV-1. Mutations at the proximal N-terminus of E1 can affect N-
glycosylation kinetics. (A) Left: Cartoon depictions of E1 N-terminal constructs 
assayed. Middle: Representative fluorographs for E1 add ASA and E2/E1 
chimera constructs. Glycosylated (1-Gly) and unglycosylated (0-Gly) species are 
labeled. Right: Plots of maximally glycosylated (1-Gly) species for: wild type N-
terminus E1 sequence with an NTT site (black), wild type N-terminus E1 
sequence with an NTS site (blue), E1 add ASA sequence with an NTS site 
(purple), and E2/E1 chimera with an NTS site (red). Error bars are ± s.e. from 3 
experiments for all constructs except E1 add ASA, which is from 1 experiment. p 
< 0.05 for E2/E1 chimera against all other E1 constructs by two-way ANOVA. (B) 
Left: Cartoon depictions of E2 N-terminal construct assayed. Middle: 
Representative fluorographs for E2 del S2 construct. Glycosylated (1-Gly) and 
unglycosylated (0-Gly) species are labeled. Right: Plots of maximally 
glycosylated (1-Gly) species for: wild type N-terminal E2 sequence with an NFT 
site (black), wild type N-terminal E2 sequence with an NFS site (blue), and E2 
del S2 sequence with an NFS site (red). Error bars are ± s.e. from 3 experiments 
for all constructs. p < 0.05 for E2 del S2 against both NFT/S wild type N-terminal 
sequences by two-way ANOVA. 
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kinetics. Since at least the E1 N-terminus is expected to form an α-helix [80], it is 
also possible that these data reflect a preferred orientation for the consensus site 
on the helix. Further experiments should utilize our established pulse-chase 
assay to identify the precise determinants that affect these shifts in N-glycan 
attachment rates. 
 
Characterizing an E3 insertion mechanism 
Another question still left unanswered is an explanation for the large 
unglycosylated pool of wtE3 in our kinetic assays. As discussed in Chapter II, it is 
possible that E3 is inserted into the ER membrane via a post-translational 
translocation system (detailed in Chapter I). To test this, we performed 
ultracentrifugation assays at 10,000 g to separate membrane bound and 
membrane free protein (Figure IV-2). Membrane free protein will remain soluble 
in these spins (S) while membrane bound proteins will pellet with the membrane 
(P). E1 is thought to be inserted by the traditional SRP/co-translational 
translocation system, and this is further evidenced by an absence of E1 in the S 
fraction, while all glycopeptide forms are found in the P fraction (Figure IV-2, 
lanes 1 and 2). However, when E3 is assayed, unglycosylated protein is found in 
the S fraction (lanes 4 and 6) with all glycopeptide forms still detected in the P 
fraction (lane 5 and 7). This membrane-free population of E3 implicates a post-
translational translocation mechanism yet to be defined. 
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Figure IV-2. E3 and E3/4 peptides are not completely membrane 
incorporated. E1, E3, and E3/4 peptides were subjected to ultracentrifugation as 
described below. E1 is only found in the pelleted fraction (P, lane 2), and not 
found in the soluble fraction (S, lane 1). E3 was pulse-chased with a standard 
protocol to use as a marker for the different glycoforms ((-), lane 3). In two side-
by-side experiments (lanes 4-5 and 6-7) E3 unglycosylated peptide is found in 
the S fraction. E3/4 unglycosylated peptide ((-) marker, lane 8) is also found in 
the S fraction, though less unglycosylated peptide appears in the P fraction than 
for wtE3 (lane 10 compared to lanes 5 and 7). All glycoforms are labeled for each 
construct. E1 and E3, n=2; E3/4, n=1. 
 
Methods: Pulse-chase assay proceeded as described in Chapter II, but plates 
for ultracentrifugation were pulsed for 3 min with 35S and chased for 10 min only. 
Cells were washed once with PBS and once with 100 mM NaCl. Plates were 
scraped and homogenized in 1 mL 0.1 M NaCo3 pH 11.5 with protease inhibitors 
using a 25.5 gauge syringe. Samples spun at 80,000 rpm for 30 min with a TLA 
100.4 rotor. Pellets were then solubilized with 720 µL low salt lysis buffer with 50 
µM Tris HCL pH 7.4. The supernatant fractions were pH adjusted to 7.4 by 
adding 0.1% HCl, then low salt lysis buffer and 50 µM Tris HCl pH 7.4 was added 
to a volume of 750 µL. The samples then underwent IP through film development 
steps as described in Chapter II. 
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We also assayed the E3/4 chimera used in Chapter II (E3 XL), which we 
found shifts E3 towards co-translational N-glycosylation. Interestingly, this 
peptide also has a large soluble unglycosylated presence in the S fraction (lane 
9), but significantly reduced levels of unglycosylated peptide in the P fraction 
(lane 10) compared to wtE3 (20% 0-Gly for E3/4 as compared to 63.5% 0-Gly for 
wtE3 in P fraction). The fact that this long C-terminal peptide also has a 
membrane-free population of unglycosylated peptide needs to be further 
explored. One intriguing possibility is that these assays are not implicating post-
translational translocation, but rather peptide topology. The large pool of 
unglycosylated E3 peptide in the P fraction could be due to peptides inserted in a 
type II orientation, possibly recognized by the TA protein machinery, blocking the 
peptide’s consensus sites from N-glycosylation. E3/4 chimeric peptides perhaps 
then could insert correctly more often, explaining the different ratios observed in 
the P fraction. More experiments to test these hypotheses will be necessary, 
particularly proteolytic assays to determine peptide topology. 
 
Elucidating KCNE N-glycosylation deficiency mutations in disease 
Lastly, a number of disease mutants in the N-terminal domains of the 
KCNE family still have unexplained etiologies. While E1 T7I was previously 
characterized as an N-glycosylation deficiency mutation [2], the molecular 
mechanisms of two mutations in E2 (T8A and Q9E) [77,123] and one mutation in 
E3 (T4A) [124] have yet to be elucidated. We assayed the E3 T4A mutant for 
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obvious deficiencies in N-glycosylation kinetics, and found this mutant to behave 
almost identically to wtE3 (Figure IV-3A). Other possible etiologies, including 
topological questions and the potential role of O-linked glycosylation, need to be 
explored to further describe this mutant. 
E2 T8A and Q9E are unique in that they cause drug-induced LQTS. 
Macrolide antibiotics, including clarithromycin and sulfamethoxazole (SMX), are 
administered as treatment for a number of bacterial infections [130]. It was found 
however, that only persons carrying E2 T8A or Q9E mutations developed LQTS 
after treatment with these drugs. Since T8A eliminates the first N-glycosylation 
consensus site, it is possible that these antibiotics are affecting the N-
glycosylation kinetics by an unknown mechanism. We began to test this 
hypothesis by expressing the E2 mutants and pretreating cells with 50 µM SMX 
from transfection through the pulse-chase. We found preliminary evidence that 
SMX might have an effect on the kinetics of N-glycosylation by a slight but 
significant decrease in co-translational N-glycosylation (Figure IV-3B); however, 
further drug optimization is still needed. Specific effects of macrolide antibiotics 
resulting in an N-glycosylation deficiency would be a novel mechanism of N-
glycosylation inhibition, and this mechanism would need to be elucidated in 
future studies. 
Overall, this thesis defines molecular determinants that effect the 
distributions of co- and post-translational N-glycosylation for type I 
transmembrane peptides. Additional characterization of these and other 
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Figure IV-3. N-terminal LQTS mutants may affect N-glycosylation kinetics. 
(A) Left: Pulse-chase fluorograph of the LQTS mutant E3 T4A. All glycoforms are 
labeled. Right: Plots of total N-glycosylation (1+2+3-Gly) for wtE3 (black) and E3 
T4A (red). wtE3 error bars are ± s.e. from 3 experiments. E3 T4A, n=1. (B) Left: 
Pulse-chase fluorograph of the LQTS mutant E2 T8A incubated with SMX (50 µM 
dissolved in ethanol) from transfection through completion of pulse-chase. 
Glycoforms are labeled. Right: Plots of maximally glycosylated (1-Gly) species 
for the equivalent glycosylation mutation E2 N6Q (black) and E2 T8A + SMX 
(purple).  p < 0.05 by two-way ANOVA. E2 N6Q error bars are ± s.e. from 3 
experiments. E2 T8A, n=1. 
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determinants for other peptide topologies – type II, water-soluble, multi-spanning 
TM – will allow for a broader, generalized understanding of N-glycosylation site 
occupancy for all TM and secretory proteins. The ability to predict success of a 
consensus site by primary sequence alone would be immensely helpful in the 
study of all glycoproteins and the identification and characterization of N-
glycosylation deficiency diseases. 
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CHAPTER AI: DETERMINATION OF THE ASSEMBLY ORDER FOR KCNQ1 
AND KCNE1 CHANNEL COMPLEXES 
 
Abstract 
 
The KCNQ1 (Q1) voltage-gated potassium (K+) channel is composed of 
four α subunits that assemble with the family of KCNE β subunits for proper 
physiological function. Q1 co-assembly with individual members of the KCNE 
family drastically alters the channel’s properties (Figure I-10), allowing Q1 to 
perform different tasks in a wide variety of tissues. Currently, little is known about 
the mechanism of assembly between Q1 and KCNE members. In particular, an 
outstanding issue to be addressed is the unusual architecture of the Q1/KCNE 
complex. It has been shown through electrophysiological studies that 
homotetrameric Q1 channels only associate with two β subunits despite the 
potential to bind in a 1:1 stoichiometry based on the four-fold symmetry of the ion 
conducting pore. To directly examine the process of Q1 channel and β subunit 
assembly, we performed cysteine-crosslinking experiments with an in vitro 
translation system to observe early assembly events and determine the order of 
KCNE1 assembly with KCNQ1. While this project was ultimately unsuccessful as 
designed, several findings could be used for future work in other systems. 
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Materials and Methods 
 
Cloning and plasmids: Human KCNQ1 and KCNE1 were cloned into 
pcDNA™3.1(-) vector and a Kozak sequence (GCCGCCACC) was added 
immediately preceding the start codon for in vitro translation. E1 contains a C-
terminal HA tag. Cysteine mutations were created using either Quikchange Site 
Directed Mutagenesis Kit or by traditional PCR cassette mutagenesis (Agilent 
Pfu Turbo) between the 5’ BamHI and 3’ XbaI sites for Q1 and between the 5’ 
KpnI and 3’ BglII sites for E1. All constructs were confirmed by DNA sequencing 
the entire gene.  
 
mRNA transcription: Plasmid DNA for Q1 and E1 was linearized with MluI for 
16 h. DNA was then extracted using phenol:chloroform by phase lock gel. The 
DNA was then precipitated with 1/10 volume 3 M NaOAc pH 5 and 1 volume 
ethanol at -80°C for 30 min, and pelleted at 14,000 rpm for 20 min at 4°C. The 
supernatant was removed and 100 µL 70% ethanol was added and again 
pelleted at 14,000 rpm for 5 min at 4°C. The supernatant was again removed and 
the pellet allowed to air dry for 10 min to evaporate the remaining alcohol. The 
pellet was dissolved in water and the transcription reaction components added 
(all Promega): 1X transcription buffer, 10 mM DTT, 1.1 U/µL RNase Inhibitor, 
1mM NTP mix, 1mM 5’ G cap, and 0.3 U/µL T7 RNA Polymerase. Reaction was 
incubated for 1 h at 37°C, another 0.3 U/µL T7 RNA Polymerase was added, and 
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reaction was incubated at 37°C for another 1h. The DNA was destroyed using 
0.2 U/µL DNase I (NEB) with IX reaction buffer and incubated 37°C for 10 min. 
The remaining RNA was then extracted by phenol:chloroform phase lock gel, and 
precipitated using 1/10 volume 3 M NaOAc pH 5 and 1 volume isopropanol 
incubated on ice for 20 min, and pelleted at 14,000 rpm for 15 min at 4°C. The 
supernatant was removed and 100 µL 70% ethanol was added and again 
pelleted at 14,000 rpm for 5 min at 4°C. The supernatant was again removed and 
the pellet spun under a vacuum for 5 min, resuspended in in 25 µL water, the 
concentration determined (Abs260/280), and the mRNA was stored at -80°C. 
 
In vitro translation assay: mRNA was denatured by heating at 65°C for 3 min 
and plunged into ice. The in vitro components were then added to a fresh tube: 5 
µg/mL - 20 µg/mL mRNA, 1/50 to 1/5 reaction volume of microsomal membranes 
(Promega) or permeabilized CHO cells (see below), 40 U/µL RNAse Inhibitor 
(Promega), 1 mM amino acid mix without methionine and cysteine (Promega), 1 
volume rabbit reticulocyte lysate (Promega), and 1,200 Ci/mmol at 10 mCi/mL 
EasyTag EXPRESS [35S] Protein Labeling Mix (MP Biomedicals). Samples were 
incubated at 30°C for 1 h, and prepared for electrophoresis by adding 2x SDS gel 
loading buffer to the sample, and 100 mM DTT (if no cross-linking was to be 
observed). Samples were analyzed by 15% SDS-PAGE and the gels were 
dehydrated for 1 h in a 30% ethanol, 2% glycerol solution.  Gels were dried for 2 
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h at 80°C, applied to film, and analyzed for autoradiography by Typhoon FLA-
9000 phosphoimager after 1-3 d. 
 
Permeabilized CHO cells: CHO cells were washed with PBS, and removed 
from plates using 0.5% Trypsin-EDTA. Cells were put on ice and 8 mL KHM 
buffer added: 100 mM KC2H3O2, 20 mM HEPES pH 7.2, 2 mM MgC2H3O2 
supplemented with 100 µg/mL soybean trypsin inhibitor (Sigma). After 5 min, 
cells were pelleted at 12,000 rpm for 3 min, and resuspended in 6 mL KHM with 
40 µg/mL digitonin and incubated on ice for 5 min. 8 mL KHM was added to 
quench, and samples again pelleted at 12,000 rpm for 3 min. Pellets were 
resuspended in 50 mM HEPES pH 7.2 and 90 mM KC2H3O2, and incubated on 
ice 10 min. Samples were again pelleted at 12,000 rpm for 3 min and 
resuspended in 100 µL KHM with 1 mM CaCl2 and 10 µg/mL staphylococcal 
nuclease and incubated at room temperature for 12 min. Samples were 
quenched with 4 mM EGTA for 2 min at room temperature, pelleted at 12,000 
rpm for 3 min, resuspended in 100 µL KHM, and stored -80°C. 
 
Transfection, cell lysis, and electrophoresis for western blots: Cells were 
passaged using 0.5% Trypsin-EDTA and plated onto 35 mm dishes at 80% 
confluency. After 24 h, CHO cells were transiently transfected with 1.5 µg E1 
and/or 0.75 µg Q1 construct DNA and 8 µL Lipofectamine in 1 mL OptiMem.  
After 6 h at 37°C, the transfection cocktail was removed and 2 mL of F12K media 
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with supplements was added and the cells were incubated for 40-45 h. Cells 
were washed in PBS (3 x 750 µL) and treated with 2.5 mg/mL N-ethylmaleimide 
for 10 min and treated with SDS cell lysis buffer: 10 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA pH 8.0, and 1% SDS supplemented with protease inhibitors 
(PMSF and LPA). Cells were lysed for 30 min with vigorous shaking at 4°C, and 
the cell debris scraped and pelleted at 14,000 rpm for 10 min at room 
temperature.  Samples were prepared by adding 100 mM DTT and 2x SDS gel 
loading buffer to the lysis sample (with DTT), or 2x SDS gel loading buffer only 
(no DTT) to a total volume of 50 µL. Samples were analyzed by SDS-PAGE (10 
or 15% gel) transferred to a nitrocellulose membrane, and blocked for 30 min in 
milk (5% nonfat dry milk in Tris-buffered saline containing 0.2% Tween-20 
(Western wash buffer)). Primary antibody (Q1 1:1,000 (Sigma) or HA (E1) 
1:1,000 (Roche)) was added overnight by diluting into Western blocking buffer. 
Membranes were then washed in Western wash buffer (3 x 6mL) for 5 min each, 
and secondary antibody (Q1 1:4,000 or HA (E1) 1:2,000) was added in Western 
blocking buffer for 45 min at room temperature. More washes were performed (3 
x 6 mL western wash buffer) and the membrane was incubated with SuperSignal 
West Dura Extended Duration Substrate (Pierce) for 5 min and the 
chemiluminescence captured using a LAS-3000 CCD camera and quantified by 
Multi Gauge software (Fujifilm). 
 
Ultracentrifugation of in vitro translation assay with sucrose cushion: In 
vitro translation performed as described above, with or without the presence of 
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microsomes. 16.5 µL 200 mM Na2Co3 was added to the 20 µL sample and 
incubated on ice for 10 min, and put over 50 µL of 100 mM Na2Co3 + 200 mM 
sucrose, pH 7.4.  Samples were centrifuged at 80,000 rpm for 5 min with a TLA 
100.4 rotor. Pellets (P) were then solubilized with 25 µL TRIS/SDS (5 mL 1M 
Tris, 3.13 mL 20% SDS, water to 10 mL) at 55°C for 30 min, then adjusted to 
final concentrations of 100 mM DTT and 2x SDS gel loading buffer for 50 µL 
loading volume. The supernatant fractions (S) were treated with 50 µL saturated 
(NH4)SO4 for 15 min on ice, then pelleted at 14,000 rpm for 10 min at room 
temperature. This pellet was then redissolved in 50 µL 5% trichloroacetic acid for 
5 min on ice, followed by a 10 min spin, and this pellet was then treated with 
same TRIS/SDS, DTT, and SDS gel loading buffer as described for the P 
fraction. Samples were analyzed by 15% SDS-PAGE and prepared for film as 
described in the in vitro section. 
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Results and Discussion 
 
The voltage-gated potassium channel, Kv1.3, has been shown to 
assemble via a dimerization of dimers pathway [131] and this mechanism has 
been speculated to be the pathway of thermodynamic choice for all tetrameric 
proteins, membrane embedded or cytosolic [132]. This preference was shown 
through in silico simulations, where it was found that assembly involving a trimer 
intermediate could result in aggregation prone intermediates if the monomeric 
population became depleted. It is thought that other potassium channels, 
including Q1 homotetramers, assemble in a similar manner to Kv1.3 given the 
homology among voltage-gated potassium channels [86]. However, it is not 
understood how the β subunits fit into the assembly mechanism, or if they alter 
the assembly pathway of the α subunits. 
KCNE peptides could be associating prior to (pre) or after (post) 
tetramerization of the Q1 α subunits. A pre-tetramerization mechanism would 
allow for co-assembly of Q1 and KCNE peptides in such a way as to explain the 
complex stoichiometry of four α subunits to two β subunits. Likewise, if the β 
subunits are incorporated by complementing a dimerization of dimers pathway of 
the α subunits, it should be possible to identify intermediate species along the 
pathway.  
To differentiate between E1 addition pre- or post-tetramerization of the Q1 
channel, we utilized a well documented in vitro translation system [133,134], 
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which simulates ER translation by combining rabbit reticulocyte lysate with 
canine microsomal membranes. Translated protein can be detected using 
radiolabeled 35S cysteine and methionine amino acids.  By examining assembly 
in vitro, we can have temporal control over translation of individual species that 
cannot be achieved in vivo by adding mRNA for each construct at different times, 
as well as the ability to slow assembly events to easily detectable levels. 
Assembly could be detected by specific cross-linking between cysteine mutants 
of Q1 (I145C in cysteine-less Q1 background) and E1 (G40C/K41C), which have 
been shown to be functionally unchanged by a cysteine substitution and cross-
link to each other when both are present [135]. These mutants were confirmed to 
cross-link when expressed in CHO cells as detected by western blot (Figure AI-
1). 
We were able to detect both Q1 and E1 in the in vitro system when Kozak 
sequences were added immediately prior to the start codon to improve 
translation (Figure A1-2A). We were also able to see E1 glycosylation was 
occurring (Figure A1-2B), and that Q1 and E1 were being incorporated into 
microsomes (Figure A1-2C). However, we were never able to detect a cross-
linked species. This could be because Q1 and E1 proteins were not being 
expressed in the same microsomes at concentrations high enough to be 
detected, or the in vitro system was chemically incompatible for cross-link 
formation (despite attempts to make a favorable cross-link environment by 
treatments with oxidized glutathione and hydrogen peroxide). We also believe 
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Figure AI-1. Q1 I145C and E1 G40C or E1 K41C can cross-link in vivo. Left: 
E1 blots for E1 constructs transfected with Q1 I145C in the presence or absence 
of 100 mM DTT. Maturely glycosylated E1/Q1 and immaturely glycosylated 
E1/Q1 cross-linked complexes were detected when lysates are not treated with 
DTT. Glycosylation states of E1 were confirmed by PNGaseF and EndoH 
treatments (not shown). These bands were absent in the presence of DTT. Right: 
Q1 blots for E1 constructs transfected with Q1 I145C in the presence or absence 
of 100 mM DTT. Q1 dimer is also detected readily along with the cross-linked 
constructs without DTT. Q1 dimer confirmed with the use of a Q1 tandem dimer 
marker (not shown). Representative blots from 3-5 experiments. 
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Figure AI-2. Q1 and E1 proteins can be detected with in vitro translation 
and incorporated into microsomal membranes, but Q1 membrane 
incorporation is limited. (A) Q1 and E1 protein can be synthesized in vitro 
when a Kozak sequence is present. (B) E1 expressed in vitro with varying 
concentrations of canine microsomal membranes (CMM). Glycoforms of E1 are 
detectable in the presence of microsomes (volume in µL). (C) Supernatants (S) 
and pellets (P) from ultracentrifugation of in vitro translated Q1 (left) and E1 
(right) proteins with and without CMMs. (D) Ultracentrifugation of increasing 
concentrations of Q1 mRNA translated in vitro with 2 µL permeabilized CHO 
cells. 
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that while the in vitro system works well for small peptides like E1, it does not 
incorporate significantly larger Q1 proteins very well, despite attempts to optimize 
Q1 mRNA with an excess of the recommended microsomal concentration or 
freshly prepared permeabilized CHO cells (Figure AI-2D) [136]. While much 
optimization of microsomes and mRNA concentrations was attempted, it is 
possible that further optimization may produce the right mix necessary for 
efficient cross-linking; however, a more relevant avenue for addressing assembly 
would be to develop an assay to temporally differentiate translation of Q1 and E1 
in vivo. This could plausibly be accomplished by engineering Q1 and E1 
inducible plasmids and detecting cross-linking by utilizing radiolabeled kinetic 
assays described in Chapters II and III. 
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CHAPTER AII: DETERMINATION OF KCNE1 SUBUNIT ORIENTATION IN 
KCNQ1/KCNE1 CHANNEL COMPLEXES 
 
Abstract 
 
KCNQ1 (Q1) is a voltage-gated potassium (K+) channel composed of four 
homomeric subunits that assemble with a KCNE (E1-E5) β subunit for proper 
physiological function. While the number of KCNE peptides in a Q1 channel 
complex is still debated, there is strong evidence that only two KCNEs assemble 
into the completed channel. It is not known where these peptides would 
preferentially reside because each Q1 channel contains four identical KCNE 
binding sites. Here, electrophysiological assays utilizing cysteine cross-linking 
pairs and small molecule modifications were employed to determine the 
orientation of E1 in the Q1 channel complex. These assays are ideal for the high 
sensitivity and detailed conductance information that can be extracted from slight 
perturbances to channel complex structure. However, the difficulties in working 
with heteromeric populations of homomeric complexes dependent on E1 cross-
linking or chemical modification produced ambiguous results that could not be 
overcome with these experimental design strategies. 
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Material and Methods 
 
Cloning and plasmids: Human KCNQ1 and KCNE1 were cloned into 
pcDNA™3.1(-) vector. E1 contains a C-terminal HA tag. Cysteine mutations and 
tandem constructs (no linker between subunits) were created using either 
Quikchange Site Directed Mutagenesis Kit or by traditional PCR cassette 
mutagenesis (Agilent Pfu Turbo) between the 5’ BamHI and 3’ XbaI sites for Q1 
and between the 5’ KpnI and 3’ BglII sites for E1. All constructs were confirmed 
by DNA sequencing the entire gene.  
 
mRNA transcription: As described in Appendix AI. 
 
Electrophysiology: Oocytes were surgically removed from Xenopus leavis frogs 
and defolliculated for 60 min using 2 mg/mL collagenase dissolved in OR2 
solution (in mM): 82.5 NaCl, 2.5 KCl, 1 MgCl2, and 5 HEPES, pH7.4. Oocytes 
were then rinsed and stored at 16°C in ND96 storage solution (in mM): 96 NaCl, 
2KCl, 1.8 CaCl2, 1 MgCl2, and 5 HEPES and supplemented with antibiotics: 50 
µg/mL gentamicin and tetracycline pH 7.4 and 3 mM glutathione (for TYP 
assays). mRNA microinjection of Q1 (12.6 ng) and E1 (6.4 ng) was performed 
after 24 h, and incubated 16°C for 40-48 h. Current was measured using Warner 
Instrument OC-725 two-electrode voltage clamp and data recorded with Digidata 
1322A and pClamp9 software (Axon Instruments). Currents were measured in 
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ND96 recording buffer (in mM): 96 NaCl, 2 KOH, 0.3 CaCl2, 1 MgCl2, 10 HEPES, 
pH 7.6, and a high K+ electrode solution (3 M KCl, 5 mM EGTA, 10 mM HEPES, 
pH 7.6). Oocytes were held at -80 mV and pulsed to +40 mV. For the TPY time 
course experiments, the cells were continually pulsed for 2 s every 30 s. For the 
TPY experiments, oocytes were (all in ND96 recording buffer): pre-incubated with 
1 mM TCEP, pH 7.6 for 5 min, washed three times, incubated with 100 µM TPY 
for 5 min, put on rig and began recording, washed in 500 µM FeSO4, washed 
with ND96 buffer, washed in 120 nM toxin, and washed with ND96 buffer. 
 
Data Analysis: Maximal current was determined by using Clampfit9 (Aon 
Instruments) software to find the amplitude measured at the very beginning of 
(for cross-linking study) and the very end of the 2 sec pulse. These 
measurements where then presented as a ratio for the cross-linking study, or the 
2 sec amplitude was plotted on a time course for the TPY study. 
 
Terpyridine (TPY) linker synthesis: TPY linker synthesis strategy was 
developed by Karen Mruk and outlined in her thesis, Chapter AII [137]. Her TPY 
linker precursors were used as material to attach the pyridyl disulfide group. 
These reactions were dissolved in dichloromethane with excess pyridyl disulfide 
and catalyzed by N,N'-Dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide (NHS) (Sigma). The full TPY-linker-pyridyl disulfide was 
purified by silica column with 4:1 chloroform to methanol, pumped down and 
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weighed to determine concentration, and dissolved in chloroform to aliquot. The 
samples were then lyophilized and stored at -20°C. 
 
Charybdotoxin (CTX) protein preparation: BL21 (DE3) cells were transformed 
with 150 ng CTX DNA and grown at 37°C for 16 h on LB agar with 50 µg/mL 
ampicillin. The entire plate was scraped for a started culture in LB with 50 µg/mL 
ampicillin and grown at 37°C until turbid, then distributed into 4 L TB (12 g/L 
bacto-tryptone, 24 g/L bacto-yeast extract, 4 mL glycerol) with 50 µg/mL 
ampicillin and grown until OD600 = 1.5. 0.5 mM IPTG (isopropyl-beta-D-
thiogalactopyranoside) was added and cells grown for 3 h. Cells were centrifuged 
at 5,000 rpm for 15 min at 4°C and pellet resuspended in 200 mL lysozyme 
buffer: 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM Na-EDTA, pH 8.0. Cells 
were incubated on ice 30 min. 50 µL 2-mercaptoethanol (BME), 50 µL pepstatin-
leupeptin (0.5 mg/mL in methanol), and 1.2 mL PMSF (4.5 mg/mL in methanol) 
was added and cells lysed by cell disruption. Lysate was spun at 14,000 rpm for 
15 min at 4°C, and 1/10 volume of 30% streptomycin sulfate added slowly while 
stirring on ice. Lysate was spun at 12,000 rpm for 20 min at 4°C, and 31 g/ 100 
mL solid ammonium sulfate added while stirring for 30 min on ice. Lysate was 
spun at 12,000 rpm for 20 min at 4°C. The pellets were rinsed with water and 
dissolved overnight in 400 mL Buffer A: 50 mM Tris-HCl pH 7.0, and 50 mM NaCl 
with 5 mM BME. A DE-52 column was preequilibrated with Buffer A and protein 
loaded at 5-6 mL/min. Protein was eluted by gradient application of Buffer B: 50 
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mM Tris-HCl pH 7.0, and 500 mM NaCl. Protein fractions were combined and 
dialyzed 20 h in dialysis buffer: 100 mM NaCl and 20 mM HEPES, pH 8.0. 
Protein was further purified through a SPS column at 3 mL/min with SPS buffer 
C: 10 mM KCl and 10 mM KPi pH 7.1 and eluted with SPS buffer D: 1 M KCl and 
10 mM KPi pH 7.1. Protein was again dialyzed 16 h in dialysis buffer. Protein was 
then subjected to HPLC purification and confirmed by mass spectrometry. 
Aliquots were made by addition of 100 mM KPi pH 7.0 to 5 mL and the OD280 
was measured and the concentration of CTX was calculated. Samples aliquoted 
appropriately and lyophilized down. Dried protein was stored on desiccant at  
-80°C. 
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Results and Discussion 
 
The number of β subunits present in the Q1 channel complex has been 
hotly debated for a number of years [138,139,140,141,142]. Previous findings 
from our lab have demonstrated through sensitive electrophysiological recordings 
that only two E1 peptides associate in a Q1/E1 channel complex [141]. This 
raises an intriguing area of study because two β subunits assembling into a 
channel complex would break the four-fold symmetry of the channel and only 
utilize two of four possible identical binding sites. Presumably, these β subunits 
could be either adjacent or opposite each other in the channel complex. It is 
thought that β subunits orienting opposite each other across the pore would be 
more likely for KCNE placement in the complex because this retains a two-fold 
symmetry, and could assemble in combination with a Q1 dimerization of dimers 
assembly model outlined in Chapter AI, but this has never been directly tested. In 
addition, the question of channel complex structure is further complicated by 
evidence suggesting that one E1 peptide could make contacts with up to three of 
the four Q1 subunits [101]. 
To determine whether E1 assembles on adjacent or opposite sides of the 
channel complex, we chose to utilized several electrophysiological approaches. 
Electrophysiology is both a more sensitive assay than biochemical counterparts 
and more quantitative [143]. First, we attempted to determine E1 subunit 
orientation using an established cysteine cross-linking pair on channel 
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complexes (Q1 V324C and E1 L42C) [101]. These constructs produce a 
conductance pattern where the channel pore is constitutively open, and this 
effect is not seen when Q1 V324C is expressed with wtE1 (Figure AII-1A). 
Because a conductance ratio can be measured from the current at the beginning 
of the voltage pulse (0 sec) and the end of the pulse (2 sec), the ratios between 
cross-linked (~1.0) and non-cross-linked channel complexes (~0.0) can be 
quantified. The placement of E1 could be determined by expressing Q1 V324C-
Q1 V324C tandem dimers with E1 L42C and comparing the measured 
conductance ratio to a generated binomial curve (where E1 would be either fully 
cross-linked or not cross-linked) created by expressing Q1 V324C monomers at 
varying ratios of wtE1/E1 L42C.  
Unfortunately, when this binomial curve was generated (Figure AII-1B), it 
would not fit to a binomial distribution, but instead fit nicely to a polynomial 
distribution. This implies that cross-linking in these Q1/E1 pairs fluctuates 
between intermediate states, and therefore is not suitable to answer an E1 
orientation question that requires only either full cross-linking or no cross-linking 
in this system for a definitive answer. 
We next attempted to determine E1 subunit orientation utilizing an 
engineered 40.3 Å chemical linker that would specifically disulfide bond with an 
external E1 cysteine (E1 T14C). A cysteine-less Q1 construct was used with this 
system. This terpyridine (TPY) based linker was designed to dimerize in the 
presence of iron [144], and would inhibit charybdotoxin (CTX) block of the 
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Figure AII-1. Q1 V324C and E1 L42C form a multi-state cross-link that 
cannot be utilized in E1 subunit orientation studies. (A) Family current traces 
for Q1 V324C expressed with wtE1 and Q1 V324C expressed with E1 L42C in 
Xenopus oocytes. Scale bars indicate 0.5 sec and 1 µA. Oocytes were held at  
-80 mV and pulsed from -100 mV to 40 mV for 4 sec every 30 sec. Dotted line 
indicates 0 µA. Quantifications for (B) were taken as a ratio of the currents 
measured at each arrow indication from the 40 mV (top) trace. (B) Conductance 
ratio (0 sec / 2 sec) of Q1 V324C expressed with varying ratios of wtE1 (0) to E1 
L42C (1). Binomial (R2 = 0.97) and Polynomial (3rd degree, R2 = 0.99) fits are 
shown. 
134
channel [145] if the linker went over the channel pore from an E1 opposite 
orientation, but would allow toxin block if E1 peptides were located adjacently 
(Figure AII-2A). The Q1 channel is predicted to be ~ 80 Å across at its longest 
from opposite subunits and ~ 60 Å across at its longest from adjacent subunits 
[146]. This chemical linker designed by K. Mruk [137] was composed of three 
distinct regions: a 2,2’:6’,2’’-terpyridine (TPY) tridentate ligand that forms a stable 
dimer with a transition metal ion [144], a peptide linker that can vary in length as 
needed, and a pyridyl disulfide leaving group which can react transiently with a 
reduced cysteine on the cell surface (Figure AII-2B). We initially chose to test our 
longest 40.3 Å linker, which is predicted to reach across any part of the channel 
complex. Unfortunately, our results were difficult to interpret because iron 
treatment to dimerize TPY caused inconsistent fluctuations in current, and toxin 
washes also showed substantial fluctuations that made definitive conclusions 
difficult (Figure AII-3). Many experiments were performed to optimize each 
concentration, solvent, and treatment order but the system continued to behave 
erratically. It is possible that further optimization of these conditions could 
eventually result in an ideal assay, but we decided to discontinue this particular 
project for the time being. 
 Determining β subunit orientation in Q1 channel complexes remains a 
interesting question to address; however, the difficulties in experimental design to 
differentiate between apparent symmetries present for a homomeric channel in 
an unknown homo- or heterogeneous channel population are challenging to 
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Figure AII-2. Schematic of TPY labeling design strategy used to determine 
E1 orientation. (A) Oocytes are pretreated with TPY that can form a disulfide 
bond with an available cysteine on E1 (T14C). At this point CTX can block the 
channel and inhibit current. Once FeSO4 is added to the bath solution, TPY 
dimerizes. If E1 is located in opposite subunits, TPY dimerization would block 
CTX access and current would be measured uninhibited. If E1 is located in 
adjacent subunits, some CTX block would be expected. (B) Schematic of TPY 
linker construct. This TPY linker can extend up to 40.3 Å. 
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Figure AII-3. Addition of iron and toxin cause erratic fluctuations in current 
after TPY oocyte labeling. Top: Two assay results showing inconsistent current 
fluctuations upon FeSO4 treatments after TPY labeling. FeSO4 also affected 
currents of oocytes not treated with TPY (not shown). Maximal current is 
measured from a 40 mV 2 sec pulse taken every 30 sec. All measurements 
normalized to the current measured after treatment with FeSO4. Bottom: One 
representative assay showing CTX treatments before and after treatment with 
FeSO4. Note that current does not recover fully after CTX treatments and 
behaves erratically after the second CTX treatment for unknown reasons, and 
FeSO4 treatment strangely reduces and then increases the current amounts. All 
graphs shown maintained less than  -0.1 µA oocyte leak throughout the assays. 
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overcome. It is possible that biochemical assays using chemical cross-linkers of 
specific lengths engineered to attach to tandem Q1 constructs and E1 peptides 
could be used to address this question, especially if native gels could be 
employed. However, given that the number of subunits in Q1/KCNE complexes 
remains an unanswered question in the field at large, a clear analysis of KCNE 
subunit orientation will be difficult to address until the number of KCNE peptides 
in the channel complex is definitively established. 
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